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of	 Exclusive	 Enteral	 Nutrition	 (EEN)	 induction	 over	 corticosteroids	 (CS)	 in	 children	 with	 CD	 is	
associated	with	better	early	MH	rates,	but	medium	to	long-term	benefits	are	not	well	established.	
We	hypothesised	that	early	complete	mucosal	recovery	after	EEN	induction	therapy	will	 lead	to	a	






Study	one:	 Importance	of	 initial	 induction	 therapy	on	medium-term	outcomes	with	 routine	early	
thiopurines	(TP)	use	is	not	well	documented	in	Paediatric	CD;	whether	choice	of	EEN	induction	over	
CS	 reduces	 relapses,	 need	 for	 rescue	 CS	 or	 Infliximab	 (IFX)	 and	 intestinal	 resection	 (IR)	 remains	
unclear.	In	this	retrospective	study	of	89	children	with	CD,	completing	induction	therapy	either	with	
CS	or	EEN,	we	compared	relapses,	need	for	rescue	CS	or	Infliximab	(IFX)	and	intestinal	resection	(IR)	
over	 the	 first	 two	 years.	 Choice	 of	 EEN	 over	 CS	 in	 the	 setting	 of	 early	 optimised	 TP	 use	 was	





Study	 two:	 	EEN	 induces	 superior	MH	 in	CD,	however,	 the	 impact	of	 EEN	 induced	early	MH	and	
early	 TP	 use	 on	 subsequent	 clinical	 outcomes	 needs	 prospective	 evaluation.In	 this	 prospective	
study	of	 twenty-six	 children,	we	 investigate	 frequency	of	early	 clinical,	biochemical,	mucosal	 and	
transmural	 remission	 of	 new	 diagnosis	 Paediatric	 CD	 following	 an	 induction	 course	 of	 EEN	with	
routine	early	TP	use.	We	compared	outcomes	of	early	responders	(Simple	Endoscopic	Score-CD	£3)	
vs.	 non-responders	 (SES-CD>3)	 at	 12	 months.	 We	 confirmed	 early	 good	 endoscopic	 response	





activity	 (PCDAI),	 C	 reactive	 protein	 (CRP)	 and	 Faecal	 Calprotectin	 (FC)	 against	 a	 validated	
endoscopic	 disease	 activity	 tool	 are	 not	 available.	 In	 this	 prospective	 sub-study,	 twenty-four	
children	 (<16	 years)	 with	 CD	 and	 a	 complete	 Ileo-colonoscopy	 at	 diagnosis	 and	 after	 induction	
therapy	 (EEN=20,	 CS=4)	 were	 included.	 Endoscopic	 disease	 activity	 was	 quantified	 using	 simple	
endoscopic	 score	 for	 CD	 (SES-CD).	 	 PCDAI	 had	 poor	 correlation	 (r=0.33);	 CRP	 (r=0.54)	 and	 FC	






for	predicting	sustained	biological	 remission	 (SR)	on	 Immuno-modulators	 (IM's)	without	 the	need	
4 
 
for	 additional	 therapies	 including	 CS,	 IFX	 or	 Intestinal	 resection	 (IR).	 Fifty-four	 newly	 diagnosed	
children	 completing	 at	 least	 6	 weeks	 EEN	 with	 paired	 clinical	 (PCDAI),	 biochemical	 (CRP)	 and	
endoscopy	scores	(SES-CD)	at	diagnosis	and	post	EEN	were	analysed.	All	commenced	IM's	early	and	





Study	 five:	 Faecal	 microbiome	 studies	 report	 EEN	 induced	 remission	 coincides	 with	 reduced	
bacterial	 diversity,	 however	 the	 mucosa-associated	 microbiome	 (MAM)	 is	 distinct	 and	 poorly	





















response	 rates	 in	 those	children	 later	 treated	with	 infliximab.	We	demonstrate	 the	 limitations	of	
currently	used	non-invasive	markers	 to	accurately	predict	MH	after	EEN.	 	We	conclude	with	sub-
analysis	 of	 the	 pre-	 &	 post	 EEN	 mucosal	 associated	 microbiome,	 which	 demonstrates	 gross	
alterations	 in	 mucosal	 microbiota	 similar	 to	 stool	 microbiome	 following	 EEN	 as	 reported	 by	
previous	studies.		We	demonstrate	the	novel	finding	that	microbial	diversity	post	EEN	in	those	with	
complete	MH	not	only	shows	contraction	in	microbial	diversity	but	a	shift	in	the	Firmicutes	family	
from	 Ruminococcaceae	 to	 Lachnospiraceae,	 a	 reduction	 in	 presumptive	 protective	 bacteria	 F	
prausnitzii	 and	 an	 increase	 in	 presumptive	 genus	 Dorea.	 The	 relevance	 of	 these	 MAM	 findings	
needs	 to	be	validated	 in	a	 larger	sample	size	but	our	pilot	data	challenges	 the	hitherto	simplistic	
assumption	 that	 mucosal	 recovery	 depends	 on	 correction	 of	 reduced	 microbial	 diversity	 and	
supports	 the	 concept	 of	 encouraging	 the	 recovery	 of	 certain	 microbial	 species	 for	 improved	
outcomes.	
This	thesis	adds	significant	and	practice	changing	clinical	and	preliminary	microbiological	data	in	the	
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onset	 Crohn's	 disease	 is	 a	 more	 severe	 phenotype	 with	 the	 additional	 issues	 of	 growth	 failure,	
delayed	puberty,	poor	bone	density	and	the	consequences	of	a	chronic	disease	commencing	at	a	
vulnerable	 period	 of	 psychosocial	 development.	 Cohort	 studies	 comparing	 the	 clinical	 course	 of	
paediatric	 vs.	 adult-onset	 CD	 confirm	 the	 more	 aggressive	 nature	 with	 extensive	 intestinal	
involvement,	rapid	progression	and	increased	disease	activity	 index,	year	by	year,	despite	the	use	
of	more	immunosuppression	(3-5).	These	observations	demand	the	need	for	both	better	treatment	
endpoints	 and	 interventions	 in	 the	 paediatric	 population.	 Mucosal	 healing	 has	 emerged	 as	 an	
important	end-point,	which	when	achieved	in	the	first	year,	leads	to	less	frequent	clinical	relapses,	
fewer	 hospitalisations,	 reduced	 surgical	 resections	 and	 lower	 risk	 of	 fistulising	 disease	 (5-7).	
Treatments	 for	 induction	 of	 remission	 in	 CD	 include	 EEN	 (exclusive	 enteral	 nutrition),	
corticosteroids	 (CS)	 and	 biologic	 agents.	 High-quality	 studies	 and	 those	 in	 paediatric	 cohorts	
comparing	steroids	and	EEN	for	induction	of	clinical	remission	show	them	to	be	equally	effective	in	
up	to	80%	of	patients	(9).	However,	clinical	remission	indicated	by	improved	symptom	control	alone	




future	 outcomes	 beyond	 12	months	 has	 not	 been	 studied.	 (11,12).	 The	major	 hypothesis	 of	 this	
thesis	 is	 that	 inducing	 early,	mucosal	 healing(MH)	with	 EEN	 followed	by	 an	 early	 introduction	of	





Poor	 concordance	 between	 Crohn’s	 clinical	 disease	 activity	 index	 (CDAI)	 and	 endoscopic	 disease	
activity	is	well	established	in	adults	with	active	CD	with	up	to	70%	of	patients	in	clinical	remission	
having	significant	mucosal	lesions.	(10,13)	The	Paediatric	Crohn’s	Disease	activity	index	(PCDAI)	is	a	
clinical	 tool	 like	 CDAI,	 that	 includes	 subjective	 variables	 and,	 unlike	 CDAI,	 PCDAI	 has	 not	 been	
validated	against	established	endoscopic	disease	activity	scores.	The	purpose	of	our	study	was	also	
to	 correlate	 these	 proxies	 with	 simple	 endoscopic	 score	 (SES-CD)	 at	 diagnosis	 and	 assess	 their	
performance	 in	predicting	endoscopic	disease	scores	after	primary	 induction	therapy	with	EEN	or	
steroids.		
Despite	 the	success	of	EEN,	 little	 is	known	about	 the	mechanisms	of	EEN	promoting	MH,	or	why	
some	 patients	 are	 non-responders.	 In	 that	 context,	 our	 understanding	 how	 the	 gut	 mucosa-
associated	 microbiota	 (MAM)	 is	 affected	 by	 EEN	 is	 relatively	 deficient.	 Many	 recent	 studies	
exploring	 the	 stool	microbiota	 during	 EEN	 in	 paediatric	 CD	 demonstrate	 reductions	 in	microbial	
diversity,	along	with	improvement	in	clinical	disease	(symptom)	activity	scores.	(14-16)	
However,	 not	 only	 is	 the	 mucosa-associated	 microbiome	 (MAM)	 distinct	 as	 it	 is	 often	 poorly	
reflected	in	stools,	but	clinical	symptom	control	does	not	equate	to	endoscopic	healing.	(10,	17-18).	
Therefore,	 an	 understanding	 of	 changes	 in	 the	 MAM	 in	 response	 to	 EEN	 intervention,	 and	 its	
relationships	 with	 endoscopic	 mucosal	 healing	 are	 essential.	 There	 are	 no	 published	 studies	










Crohn’s	 Disease	 and	 Ulcerative	 Colitis	 are	 two	 major	 groups	 of	 chronic	 inflammatory	 bowel	
disorders	 (IBD)	affecting	almost	75,000	Australians	 (Crohn’s	Colitis	Australia,	March	2013).	 IBD	 in	
Australia	 is	more	common	than	road	traffic	accidents	and	almost	as	common	as	Type	1	Diabetes	
with	 the	estimated	economic	cost	of	 IBD	 to	Australia	of	over	2.7	Billion	 (“The	Economic	Costs	of	
Crohn’s	Disease	and	Ulcerative	Colitis”,	Access	Economics,	9	June	2007).		







multiple	 lifestyle	 factors	 linked	 with	 risk	 of	 developing	 CD	 such	 as	 method	 of	 birth,	 antibiotic	
exposure,	smoking	and	diet.	Recent	prospective	lifestyle	and	dietary	risk	cohort	studies	suggests	a	
preventative	 role	 for	 fiber	 intake	 from	 fruits,	 vegetables	 and	 an	 increase	 risk	 of	 CD	with	 animal	
protein	 intake	 (24,	 25).	 Diet	 is	 the	 most	 frequently	 reported	 risk	 factor	 associated	 with	
inflammatory	bowel	disease	flare	by	patients,	yet	there	is	a	paucity	of	prospective	data	examining	








A	widely	 accepted	 hypothetical	model	 of	 CD	 pathophysiology	 suggest	 it	 is	 an	 immune	mediated	
































and	 immune	 system	 contributing	 to	 pathogenesis	 of	 CD	 –	 adopted	 from	Boyapati	 (F1000Prime	
rep.)30	
	
A	 significant	 progress	 has	 been	made	 in	 genetics	 of	 CD,	with	 over	 160	 genetic	 susceptibility	 loci	
described	with	 the	 help	 of	 large	 population	 based	GWAS.	 These	 genetic	 variants	 are	 involved	 in	
diverse	 immune	 pathways	 such	 as	 paneth	 cell	 function	 (NOD2),	 autophagy	 (ATG16L1),	 epithelial	
barrier	 function	 (PTGER4)	 innate	 immunity	 (MST1,	 MAST3,	 CARD9),	 phagocytosis	 NCF4,	 NCF2,	
adaptive	immunity	(Il23R,	NKX2-3)	and	antigen	presentation	(DENND1B,	LRRK2)	(30).		Advances	in	
high	 throughput	 sequencing	 have	 also	 enhanced	 our	 understanding	 of	 how	 microbiota	 can	
contribute	 to	 pathophysiology	 of	 IBD.	 Reduction	 in	 microbial	 diversity	 have	 been	 consistently	
processing of intracellular bacteria such as Listeria
monocytogenes [18]. In humans, a cohort study found a
significant association between NOD2 risk alleles and
increased abundance of Enterobacteriaceae [39]. In
mice, NOD2 deficiency is also associated with ileal
dysbiosis [40–42] but this is not consistently replicated
[43,44]. NOD2 facilitates autophagic targeting of
bacterial pathogens via binding to the autophagy
protein ATG16L1, to be discussed later [22,45].
The NOD2 interactome is incredibly complex (Table 1),
and all respective network functions and interactions are
potentially important in CD, as they are potential novel
therapeutic or ‘druggable’ targets [12,27,46–50]. Overall,
Figure 2. Molecular mechanisms in the pathogenesis of Crohn’s disease (CD)
(A) A number of CD susceptibility genes have been identified (see text). Of these, NOD2 has the strongest association. (B) Microbial dysbiosis is
characterized by decreased diversity and changes in abundance of particular bacterial species. Increased levels of AIEC with adherent (via CEACAM6)
and invasive properties are resistant to subsequent phagocytic killing, leading to cytokine responses and inflammation. (C) Environmental (and genetic)
factors affect microbial dysbiosis and lead to epithelial barrier dysfunction, including affecting the secreted barrier. (D) One major theory of how
defective NOD2 le ds to CD: nor ally, NOD2 se ses MDP activating a number of innate immune responses and bacterial kil ing; defective NOD2 leads
to defects in these pathways, resulting in persistence of intracellular bacteria and effects on antimicrobial functions in the lumen. (E) Another major
theory on NOD2: activation via MDP leads to modulating effects on the innate immune system, including suppression of cytokine effects (for example,
IL-23-driven Th17 respons s), suppression of o her PRRs (for example, TLR-2 and TLR-4 responses), and induction of tolerance (via IL-10 and decreased
TGF-b). (F) Increased IL-23 production can lead to increased Th17 responses through a number of pathways, including ILC and CD4+ T cells via the
IL-12Rb1/IL-23R receptor. IL-23 inhibits Treg cell/IL-10 responses, which are responsible for mucosal homeostasis as well as suppressive effects on
B cells, T cells, and monocytes. NOD2 may suppress IL-23-driven Th17 responses, but in defective NOD2 these may be unrestrained; see (E).
(G) Specific microbes (such as SFB and Clostridium) as well as microbial products (such as butyrate and PSA) can induce particular innate immune
responses. SFB preferentially induces Th17 responses; Clostridium (reduced in CD), butyrate, and PSA (produced by Firmicutes and Bacteroidetes, which
are reduced in CD) potently induce Treg cell responses. (H) NOD2 recruits ATG16L1 to the plasma membrane to initiate xenophagy. Normal PC
function, including release of AMP, relies on autophagy; the T300A variant in ATG16L1 seen in some CD patients leads to increased cleavage and
defective autophagy. (I) UPR and autophagy help regulate ER stress as compensatory mechanisms. Excessive ER stress can overwhelm autophagy, leading
to defective PC function. Arrows ↑ and ↓ indicate findings in CD. AMP, anti-microbial peptide; ATG16L1, autophagy-related 16-like 1 gene; CD, Crohn’s
disease; CEACAM6, carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross-reacting antigen); ER, endoplasmic reticulum;
IL, interleukin; ILC, innate lymphoid cell; MDP, muramyl dipeptide; NOD2, nucleotide-binding oligomerization domain containing 2; PC, plasma cell;
PRR, pattern recognition receptor; PSA, polysaccharide A; SFB, segmental filamentous bacteria; TGFb, transforming growth factor-beta; Th17, T helper
17; TLR, Toll-like receptor; Treg, regulatory T; UPR, unfolded protein response.
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demonstrated	 in	 CD	 with	 specific	 taxonomic	 shifts	 with	 reduced	 abundance	 of	 firmicutes	 and	
bacteroidetes,	although	it	is	unclear	if	these	microbiota	changes	are	the	cause	or	effect	of	disease.		









a	 distinct	 phenotype	 when	 compared	 to	 Adult-onset	 CD	 (AO-CD),	 with	 the	 additional	 issues	 of	
growth	 failure,	 delayed	 puberty,	 poor	 bone	 density	 and	 the	 consequences	 of	 a	 chronic	 disease	
commencing	 at	 a	 vulnerable	 period	 of	 psychosocial	 development.	 We	 briefly	 outline	 the	 key	
























































































































































Cohort	 studies	 comparing	 the	 clinical	 course	 of	 paediatric	 vs.	 adult-onset	 CD	 confirm	 a	 more	
aggressive	 nature	 with	 pan-enteric	 involvement	 (Ileo-colonic	 and	 Upper	 GI	 disease),	 rapid	








One	 in	 three	 children	 will	 have	 stricturing	 or	 fistulising	 disease	 behaviour	 at	 diagnosis	 with	 a	
cumulative	probability	of	this	doubling	over	the	next	7-11	yrs	(3,	41).	Anatomical	extension	of	the	
disease	 is	reported	in	31-39%	children	during	follow	up	(3,	41).	A	recent	French	Paediatric	cohort	





















(40-44).	 	Wide	 variations	 in	 linear	 growth	 delay	 could	 be	 secondary	 to	 heterogeneity	 including;	





the	 use	 of	 steroids.	 Using	 different	 criteria,	 impaired	 final	 adult	 height	 is	 reported	 in	 19-36%	 of	
Children	(45-52).	In	a	large	retrospective	study	from	the	UK,	almost	20%	of	Paediatric	onset	CD	did	
have	final	adult	height	>	8.0	cm	below	their	target	height	strongly	correlating	to	delay	in	diagnosis	
and	 presence	 of	 extensive	 small	 bowel	 disease	 (46).	 Another	 recent	 prospective	 US	 longitudinal	
growth	cohort	study	in	Paediatric	Onset	CD	concluded	that	only	11%	remain	stunted	in	adulthood	






was	 not	 recorded	 in	 almost	 half	 (28,	 43%)	 of	 their	 growth	 impaired	 IBD	 cohort	 (n=65)	 thus	
potentially	underestimating	the	true	prevalence	of	stunting	in	adulthood.	It	is	also	well	known	that	
choice	 of	 EEN	 over	 CS,	 leads	 to	 positive	 growth	 outcome	 in	 a	 short	 term	 but	 long	 term	 studies	
evaluating	final	adult	growth	potential	are	lacking.		Adult	height	Z	scores	were	found	to	be	similar	(-
0.39	vs.	-0.29)	between	a	recent	North	American	and	a	previous	English	cohort	study,	where	EEN	is	








EEN	 is	not	only	effective	 in	 inducing	clinical	 remission	but	provides	superior	mucosal	healing	and	
significantly	better	nutrition	and	bone	mineral	density.	(11,	12,	54)	Over	the	last	four	decades	there	
have	been	numerous	randomised	and	non-randomised	studies	demonstrating	the	effectiveness	of	
various	 elemental,	 semi-elemental	 and	 polymeric	 liquid	 diets	 as	 the	 sole	 source	 of	 nutrition	 in	
achieving	 remission	 in	 Crohn's	 disease.(11,12,66-81)	 Despite	 initial	 studies	 and	 systemic	 reviews	
suggesting	EEN	to	be	less	efficacious	than	traditional	therapy	with	CS	at	inducing	clinical	remission,	









Despite	 being	 established	 as	 a	 safe,	 effective	 non-pharmacological	 therapy	with	 greater	mucosal	
healing	 EEN	 is	 not	 uniformly	 adopted	 as	 a	 primary	 induction	 therapy	 for	 children	 with	 CD.	
International	 surveys	 clearly	 demonstrate	 contrasting	 practices	 with	 only	 4%	 of	 North	 American	





The	 Enteral	 nutrition	 working	 group	 of	 North	 American	 Society	 of	 Paediatric	 Gastroenterology	





by	providing	 complete	bowel	 rest	 separate	 from	nutritional	 restitution.	 This	 putative	mechanism	
was	first	challenged	by	a	randomised	controlled	trial	in	a	small	number	of	Adults	reporting	similar	
clinical	 remission	 in	 those	 on	 TPN	with	 complete	 bowel	 rest	 vs.	 TPN	with	 low	 residue	 diet	 (60).	
Equivalent	 clinical	 remission	at	discharge	and	at	1	 year	 follow	up	were	demonstrated	 in	 another	
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with	 or	 without	 bowel	 rest	 promotes	 clinical	 remission	 in	 a	majority	 of	 patients.	 Partial	 enteral	



















One	of	 the	 first	 controlled	 trial	 by	O'Moráin	 and	 colleagues	demonstrated	 the	 similar	 efficacy	of	
elemental	diet	(ED)	to	CS	and	suggested	that	ED	avoids	continuous	foreign	antigenic	stimulation	to	
a	 breached	 intestinal	 barrier	 in	 those	with	 CD,	 thus	 avoiding	 a	 cascade	 of	 uncontrolled	mucosal	
inflammatory	 response	 (64).	 This	 hypothesis	 was	 disproven	 by	 further	 controlled	 trials	 and	 a	
subsequent	 systemic	 review	confirmed	similar	 remission	with	elemental	 and	non-elemental	diets	
(Odds	 ratio	 1.10;	 95%	 CI	 0.69%–1.75%)	 (64).	 Non-	 elemental	 diets	 are	 less	 expensive,	 more	




The	 contention	 that	 quantity	 and	 quality	 of	 fat	 in	 EEN	 potentially	 impacts	 pro	 and	 anti-
inflammatory	cytokine	pathways	and	thus	influence	therapeutic	response	has	also	been	subjected	





gene,	 diet	 and	microbiome	 to	 inflammatory	 bowel	 disease.	 This	 study	 in	 genetically	 susceptible	








compared	 to	 those	 with	 long-standing	 disease	 (50-58%),	 although	 recent	 studies	 report	 similar	
induction	remission	and	relapse	rates	(66,69-72).	Cameron	et	al.	reported	a	greater	improvement	in	
weight	Z	score	with	first	vs.	second	course	of	EEN	(181).	When	considering	re-induction	therapy	at	






disease	 compared	 to	 isolated	 colonic	 disease	 (73).	 Further	 studies	 have	 not	 replicated	 similar	
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course	 of	 EEN	 (59	
vs.	40,	P	<	0.0001)		
higher	 3	 months.	
remission	 in	 those	 with	
first	vs.	second	course	of	
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but	 not	 colonic	 (P	 =	
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with	 studies	 reporting	 enteric	 fistula	 closure,	 clinical	 remission	 and	 reduced	 surgical	 resection	 in	
medically	 refractory	 adults	 with	 CD	 (75-76).	 In	 1984,	 the	 first	 controlled	 trial	 ascertained	 the	
comparable	efficacy	of	elemental	diet	to	steroids	reporting	clinical	remission	rates	of	80	%	in	both	
arms	 (61).	 Following	 this,	 other	 controlled	 trials	 in	 adults	 with	 larger	 numbers	 (except	 for	 one	
study)	 did	 not	 validate	 these	 findings	 (64,75-81)	 and	 a	 Cochrane	 review	 stated	 "including	 192	
patients	treated	with	EN	and	160	treated	with	steroids	yielded	pooled	OR	(0.33,	95%	CI	0.21-0.53)"	
thus	 favouring	 steroids	 over	 EEN	 in	 inducing	 clinical	 remission	 (65).	 The	 limitations	 of	 the	 above	
conclusions	are;	high	EEN	withdrawal	 rates	 (39%	 in	one	 large	RCT),	 concurrent	 intervention	with	
Sulphasalazine	in	those	on	corticosteroids	and	heterogeneous	definition	of	clinical	remission.	Also,	
one	 could	 argue	 that	 a	 negative	bias	 is	 introduced	when	 comparing	 EEN	 results	with	CS,	 only	 in	
those	 prepared	 to	 attempt	 EEN	 and	 not	 just	 randomised.	 On	 performing	 non–intention	 to	 treat	
analysis	aiming	to	estimate	the	true	effect	of	EEN	in	those	adhering	to	the	diet	we	calculated	similar	
clinical	 remission	 rates	between	CS	vs.	EEN	 in	adults	with	CD	 (100/148,	67.5%	vs.	135/172,	78%)	
and	NNT=	9.2	 (that	 for	every	9	patients	 treated	with	EEN,	1	will	not	enter	 into	clinical	 remission	
compared	to	steroids).	Therefore,	EEN	is	effective	in	inducing	clinical	remission	in	adults	with	CD	in	
48	%	(100/206)	of	those	attempting,	67	%(	100/148)	in	those	accepting	this	treatment	vs.	78%	with	















































































































































































Despite	 conclusions	 of	 a	 Cochrane	 review	 suggesting	 EEN	 is	 inferior	 to	 CS	 to	 induce	 clinical	
remission,	 systematic	 reviews	 including	 children	 report	 the	 similar	 clinical	 efficacy	 of	 EEN	 vs.	 CS	































































































The	endoscopic	disease	 remains	 active	 in	 the	majority	of	 asymptomatic	patients	 treated	with	CS	
(10,	87)	and	studies	have	also	confirmed	greater	endoscopic	and	histological	remission	in	CD	after	
treatment	 with	 EEN	 (11-12,63,	 88-90).	 A	 randomised	 controlled	 trial	 comparing	 endoscopic	





the	 EXTEND	 trial	 with	 Adalimumab	 for	 adults	with	moderate	 to	 severe	 CD,	 a	 positive	 predictive	
effect	of	early	(12	weeks)	mucosal	healing	on	Week-52	outcomes	was	demonstrated.		In	this	study,	
a	"1-point	increase	in	Week-12	SES-CD	score	was	associated	with	a	5.0-point	increase	in	Week-52	
CDAI	 score	 (p<0.05)".	 Conversely	 higher	 Week-12	 SES-CD	 scores	 were	 associated	 with	 reduced	
Odds	(OR=0.6,	p<0.05)	of	Week-52	remission	(91).	These	observations	highlight	the	importance	of	










































































































The	ultimate	benefit	of	any	treatment	 in	CD	would	be	 in	 its	ability	 to	mitigate	recurrent	relapses	
contributing	 to	 cumulative	 long-term	 bowel	 damage.	 Retrospective	 observational	 studies	 with	
longer	follow	up	comparing	CS	and	EEN	induction	therapy	suggest	sustained	clinical	remission,	40-
60%	 corticosteroid-free	 remission,	 better	 linear	 growth,	 reduced	 relapses	 and	 lower	 cumulative	
need	for	corticosteroids	with	EEN	(92-95).	However,	it	remains	unknown	if	the	early	choice	of	EEN	

























































A	 paediatric	 controlled	 study	 suggested	 a	 lower	 clinical	 relapse	 at	 18	months	 (9%	 Vs	 47	 %)	 for	
children	 started	 on	 early	 6MP	 (<8	weeks)	 vs.	 no	 6MP	 after	 CS	 induction	 therapy	 (96).	 However,	
more	 recent	 data	 is	 less	 convincing	 of	 benefits	 of	 early	 IM's	 use	 on	 subsequent	 outcomes.	 A	
prospective	randomised	study	in	147	adults	with	disabling	CD,	early	Azathioprine	therapy	vs	later,	
"on	demand"	Azathioprine	was	not	associated	with	better	outcomes	including;	remission	rate	(61%	
Vs	 50%,	 p=NS);	 anti	 TNF	 use,	 (29%	 Vs	 26%);	 and	 surgery	 (11%	 Vs	 21%,	 p=0.11)	 (98).	 However,	





Mechanisms	 behind	 EEN	 induced	 clinical	 and	mucosal	 remission	 in	 CD	 remain	 elusive.	 Proposed	







Several	 studies	 have	 shown	 EEN	 induced	 clinical	 remission	 in	 CD	 closely	 parallels	 rapid	
improvement	of	surrogate	systemic	inflammatory	markers	like	CRP,	ESR,	and	Albumin	(85,	88,	92,	
100).	 	 The	 contention	 that	 resolution	 of	 the	 systemic	 inflammatory	 response	 in	 CD	 occurs	 as	 a	
consequence	 of	 improvement	 in	 gut	 inflammation	was	 further	 tested	 in	 several	 other	 paediatric	
and	 adult	 studies.	 Fell	 et	 al	 were	 the	 first	 to	 comprehensively	 demonstrate	 improvement	 of	
endoscopic	 and	 histological	 CD	 activity	 closely	 coincides	 with	 fall	 of	 mucosal	 pro-inflammatory	
cytokines	m-RNA	(IL-1,	IFN-γ,	IL-8)	in	children	before	and	after	8	weeks	of	EEN	(88).	Another	study	
in	adults	with	active	CD	also	demonstrated	reduced	mucosal	pro-inflammatory	cytokines	IL-1β,	IL-6,	
















adult	 patients	 with	 CD,	 UC	 and	 control	 samples	 observed	 an	 increased	 ratio	 of	 the	 anti-
inflammatory/pro-inflammatory	 cytokines	 (IL-1	 receptor	 antagonist/IL-1β)	 only	 in	 tissue	 with	 CD	
thus	providing	compelling	evidence	of	EEN's	direct	anti-inflammatory	properties	(100).	A	summary	

























gold	 standard	 for	 assessing	 mucosal	 inflammation	 is	 endoscopy,	 however	 repeat	 endoscopy	 is	
invasive	 therefore	 surrogate	 markers	 are	 essential	 to	 assess	 therapeutic	 response.	 FC	 is	 an	
established	 surrogate	 faecal	 marker	 that	 strongly	 correlates	 with	 endoscopic	 and	 histological	
disease	 activity	 (103).	 Normalisation	 of	 FC	 is	 a	 dependable	 marker	 of	 MH,	 suggested	 by	 a	
colonoscopic	 study	 in	 asymptomatic	 adult	 CD	 patients	 where	 a	 normal	 FC	 reliably	 predicted	
histological	remission	in	85%	of	patients	(104).	There	is	limited	data	on	therapeutic	efficacy	or	risk	
prediction	analysis	based	on	FC	in	CD.		A	Finnish	study	examined	the	effect	of	CS	therapy	on	FC	in	
15	 children	 with	 inflammatory	 bowel	 disease	 and	 concluded	 that	 a	 majority	 of	 children	 had	
elevated	FC	despite	being	in	clinical	remission	(102)	In	a	large	prospective	multicentre	study	of	101	
children	with	UC,	 FC	 and	 other	 novel	 faecal	markers	 did	 not	 add	 further	 to	 the	 clinical	 index	 in	
predicting	corticosteroid	response	(106).	In	a	small	prospective	study	in	children	with	CD,	significant	
quantitative	 reduction	 in	 FC	 at	 1	 and	 2	 months	 after	 EEN	 correlated	 with	 complete	 clinical	
remission,	18%	drop	of	baseline	FC	at	1	month	predicted	a	successful	clinical	response	to	EEN	(107).	
Another	 small	paediatric	Spanish	study	 found	a	non-significant	 reduction	of	FC	 in	10/14	 (70%)	of	
clinical	responders	(108).	The	absence	of	endoscopic	correlation,	concurrent	medication	use,	small	
numbers	and	inclusions	of	new	and	relapsing	patients	limits	the	conclusions	from	all	studies	where	
clinical	 outcomes	 are	 the	 sole	 marker	 of	 remission.	 Further	 validation	 studies	 to	 examine	










A	 healthy	 epithelium	 maintains	 a	 physical	 and	 immunological	 barrier	 to	 harmful	 bacteria	
adequately	 sensing	 and	 reacting	 to	 harmful	 stimuli.	 Impaired	 intestinal	 epithelium	 integrity	 is	
increasingly	 appreciated	 as	 a	 major	 factor	 contributing	 to	 CD	 pathogenesis	 as	 it	 represents	 an	
interface	of	genetic,	immune	and	environmental	factors.	Whether	a	defective	intestinal	epithelium	
barrier	 is	 a	 consequence	 of	 the	 inflammatory	 response	 or	 a	 primary	 epithelial	 defect,	 triggering	
secondary	inflammatory	response	is	not	clear.	It	appears	that	a	“leaky	gut”	is	an	early	phenomenon	
in	the	development	of	disease,	probably	genetically	driven	and	triggered	further	by	environmental	
factors	 such	 as	 luminal	 antigens	 or	 bacteria.	 Support	 for	 this	 comes	 from	 studies	 indicating	
increased	intestinal	permeability	in	healthy	relatives	of	patients	with	IBD	and	observations	that	this	
could	be	 related	 to	underlying	genetic	mutations	 (109-110).	Defects	 in	epithelial	barrier	 function	
are	indirectly	measured	by	oral	administration	of	a	non-absorbable	test	substance	and	subsequent	
measurement	 in	 urine.	 Children	 with	 active	 CD	 have	 perturbation	 of	 normal	 intestinal	 barrier	
function	 as	 suggested	 by	 abnormal	 lactose/rhamnose	 sugar	 permeability	 test	 (111).	 Impaired	
intestinal	 permeability	 also	 positively	 correlates	 with	 CD	 activity	 and	 is	 also	 associated	 with	
increases	likelihood	of	clinical	relapse	(112-114).	EEN	leads	to	rapid	and	significant	improvement	in	
lactose/rhamnose	permeability	ratio	normalizing	to	a	normal	 level	 in	almost	50%	of	children	with	









CD	as	 suggested	by	 increased	production	of	 interferon-γ	 (IFN-γ),	 tumor	necrosis	 factor-α	 (TNF-α)	
and	interleukin-17	(IL-17)	from	ileo-colonic	biopsies	of	patients	with	CD	(117).	FoxP3+	T	regs	cells	
can	modulate	the	Th1/Th2/Th17	response	(Figure	1.2)	hence	are	pivotal	in	maintaining	gut	immune	
tolerance;	 the	 number	 of	 CD25bright	and	 FoxP3+	cells	 are	 higher	 in	 the	 lamina	 propria	 of	 patients	
with	CD	than	in	normal	controls	and	an	increase	is	observed	in	those	with	active	CD	(115-116).		In	
one	 previous	 trial,	 mucosal	 FOXP3	 expression	 was	 significantly	 increased	 in	 those	 treated	 with	
Infliximab	vs.	EEN	(116).	EEN	therapy	also	leads	to	down-regulation	of	mucosal	IL-6	and	serum	TGF-	
β1	expression,	key	mediators	of	CD25+	T	regulatory	cells,	ultimately	impacting	Th1/Th17	helper	cell	












“Differentiation	 of	 T-cell	 Subsets.	 Upon	 stimulation,	 naïve	 CD4+	 T-cells	 differentiate	 into	 3	main	
subsets,	 Th1,	 Th2,	 and	 Th17	 cell.	 IL-12	 induces	 the	 formation	 of	 IFN-γ	 producing	 Th1	 cells.	 IL-23	
promotes	the	development	of	an	IL-17	producing	CD4+	helper	T	cells.	IL-4	induces	STAT6	activation,	
promoting	 the	expression	of	GATA-3,	which	 feeds	 forward	 to	 induce	 IL-4	expression	and	Th2	cell	
differentiation.	An	EBI3-associated	cytokine	was	hypothesized	to	be	necessary	for	activation	of	IL-











Despite	 enormous	 progress	 in	 understanding	 the	molecular	 pathogenesis	 of	 IBD	 its	 exact	 cause	
remains	 elusive.	 The	most	 accepted	mechanistic	 model	 is	 that	 chronic	 gut	 inflammation	 results	
from	 an	 intolerant	 innate	 and	 adaptive	 immune	 response	 to	 commensal	 or	 pathogenic	 enteric	




Failure	 to	 develop	 experimental	 colitis	 in	 various	 germ-free	murine	models	 and	 improvement	 of	




There	 is	 enormous	evidence	 that	 "dysbiosis"	 contributes	 to	 the	pathogenesis	of	 IBD.	 The	human	
microbiota	 is	 characterised	 by	 four	major	 phylum	 Firmicutes,	 Bacteroidetes,	 Proteobacteria	 and	






confirmed	 stool	 microbiota	 signatures	 highly	 specific	 to	 adult	 CD,	 with	 predominant	 loss	 of	
beneficial	 Faecalibacterium,	 Christensenellaceae,	 Methanobrevibacter,	 Oscillospira	 and	 gain	 of	
pathobionts	 Fusobacterium	 and	Escherichia	(126).	 On	 the	 other	 hand,	 Gevers	et	 al.	 reported	 CD	
61 
 
specific	 mucosa	 associated	 microbiota	 (MAM)	 in	 treatment	 naive	 children	 with	 abundance	 of	
“pathobionts”	including	Enterobacteriaceae,	Pasteurellaceae	Fusobacteriaceae	and	Veillonellaceae	









Modification	of	 intestinal	microflora	 is	proposed	as	a	 therapeutic	mechanism	of	action	of	EEN	 in	
CD.	 Previous	 investigations	 relying	 on	 culture	 driven	 methods	 failed	 to	 confirm	 microbiota	
modification	 following	 EEN	 (127-128).	 However,	 availability	 of	 culture	 free	 techniques	 like	
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PCR/DGGE	and	PCR/TGGE	made	 it	 possible	 to	 further	 investigate	 this	 putative	mechanism	 (128).		
Most	 recent	 paediatric	 studies	 have	 utilised	 next	 generation	 sequencing	 targeting	 16SrRNA	
(13,15,132-134).	Multiple	 studies	exploring	utilising	 the	 stool	microbiota	during	EEN	 in	paediatric	
CD	 have	 reported	 reduction	 in	 bacterial	 diversity,	 loss	 of	 Firmicutes,	 Bacteroides/Prevotella	 and	
increase	 in	 Bacteroidetes	 (Table	 1.10).	 Another	 consistent	 but	 paradoxical	 report	 is	 the	 greater	
reduction	in	biodiversity	in	those	with	improvement	in	clinical	disease	activity	scores	(13-15).		
These	 alterations	 include	 the	 depletion	 of	 specific	 bacteria	 such	 as	 Faecalibacterium	 prausnitzii,	
which	 is	widely	 considered	 to	 be	 beneficial	 for	 its	 anti-inflammatory	 properties	 (13,14,135),	 and	
contrast	with	studies	by	Schwerd	et	al.	and	other	adult	CD	studies	(132,136).			
The	 mucosa-associated	 microbiome	 (MAM)	 is	 now	 accepted	 to	 be	 distinct	 from	 the	 faecal	
microbiome	 (16-17)	 and	 there	 are	 currently	 no	 published	 studies	 correlating	 post-EEN	 induction	
endoscopic	disease	activity	scores	and	parallel	changes	in	MAM.	A	single	case	report	described	the	
ileal	microbiome	 changes	 pre-	 and	post-EEN	 in	 a	 newly	 diagnosed	 child	with	 CD,	 compared	 to	 a	
single	 healthy	 control	 (137).	 The	 pre-EEN	MAM	 in	 the	 child	 with	 CD	 showed	 reduced	microbial	
diversity,	increased	levels	of	Proteobacteria	and	lower	levels	of	Bacteroidetes	species	compared	to	

















Adequate	 therapeutic	 end	 points	 for	 any	 lifelong	 chronic	 relapsing	 illness	 like	 CD	 is	 not	 just	 short-term	 symptomatic	 relief	 but	 long-term	
modification,	 amelioration	 of	 disease	 progression.	 In	 this	 chapter,	 we	 review	 the	 natural	 history	 of	 CD	 and	 its	 further	 relevance	 in	 the	
paediatric	 age	 group.	 	 Before	 choosing	 therapeutic	 targets	 in	 CD,	 it	 is	 important	 to	 conceptualise	 a	 theoretical	 stepwise	 progression	 of	



































with	 steroids	 (10).	 Another	 prospective	 study	 from	 the	 same	 group	 further	 reaffirmed	 the	 poor	 relationship	 between	 clinical	 recurrence,	
biochemical	 remission	 and	 endoscopic	 healing	 (138).	 In	 a	 retrospective	 cohort	 study,	 Allez	 et	 al.	 (139)	 concluded	 that	 severe	 endoscopic	
lesions	(deep	ulceration	of	>10%	mucosal	surface)	predict	a	higher	risk	of	colectomy.	Clinical	disease	activity	tools	like	PCDAI	include	variables	



































































Trials	evaluating	mucosal	healing	with	other	CD	 therapies,	 apart	 from	EEN,	are	 limited	 to	adults.		
There	are	no	placebo	controlled	trials	using	IM’s	or	biologics	with	similar	endpoints	 in	children.	A	
recent	 paediatric	 study	 including	 66	 moderate	 to	 severe	 CD	 patients	 failing	 steroids	 and	


































































































































































































































































































































Prednisolone	1mg/kg/day	 142	 Active	 CD	
(CDAI>200)	
































and	 then	 5	 or	 10	
mg/kg/8wks	 Vs	 Infliximab	
5mg/kg/	 at	 0	 followed	 by	



































placebo	 IV	 vs	 Infliximab	
5mg/kg	 IV	 at	 0,2,6	 then	





























































every	 2	 weeks	 VS	
Adalimumab160mg/80	mg	












































































































MR	 Enterography	 can	 reliably	 measure	 Ileocolonic	 transmural	 disease	 activity	 accurately	






relapses,	 fewer	 hospitalisations	 and	 reduced	 surgical	 resections.	 Use	 of	 Exclusive	 Enteral	
Nutrition	(EEN)	induction	over	corticosteroids	in	children	with	Crohn’s	disease	(CD)	is	associated	
with	 greater	 early	mucosal	 healing	 (MH)	 but	 long-term	 benefits	 are	 not	 well	 described.	 The	
overarching	goal	of	 this	 thesis	was	 to	 investigate	benefits	of	EEN	and	early	 thiopurine	use	on	






















Does	 the	degree	of	 early	mucosal	 healing	with	 Exclusive	 Enteral	Nutrition	 correlates	with	
long	term	outcomes	in	Paediatric	Crohn’s	disease?		
Question	5:		




















completing	 minimum	 of	 six	 weeks	 of	 EEN	 and	 a	 paired	 clinical,	 endoscopic	 assessment	 were	
included.		
For	 study	3,	 a	 convenience	sample	of	24	children,	who	had	 luminal	CD	quantifiable	on	complete	
Ileo-colonoscopy	 and	 paired	 Paediatric	 Crohn’s	 disease	 activity	 index	 (PCDAI),	 C	 reactive	 protein	
(CRP),	Faecal	calprotectin	(FC)	and	Endoscopy	at	diagnosis	and	after	8	weeks	of	induction	therapy	
were	 analysed.	 Study	 5	 is	 a	 pilot	 sub-study	 including	 treatment	 naïve	 children	 (n=8)	 with	














• CD cohort , diagnosed prior to Nov 2009 =93
• New diagnosis CD, during Nov 2009-Nov 2012 = 42
• New diagnosis CD , Dec 2012-Dec 2014=48
Study 1: 89 completing EEN or CS with early Thiopurines
Two-year outcomes After Exclusive Enteral Nutrition Are Superior
to Corticosteroids in Pediatric Crohn's Disease Treated Early with thiopurines




• Infliximab for complex perianal CD=2
Studies 2 : 26 completing EEN
• Exclusive enteral nutrition induces early clinical, mucosal and transmural
remission in paediatric crohn’s disease
Study 3: 20 EEN and 4 CS therapy
• Predicting Endoscopic Crohn's Disease Activity Before and After Induction
Therapy in Children: A Comprehensive Assessment of PCDAI, CRP, and
Fecal Calprotectin
Study 5 : 8 paired mucosal sample pre and post EEN
• The Relative Abundances of Dorea and Faecalibacterium spp. in the
Mucosa Associated Microbiome of Newly Diagnosed Children with
Crohn's Disease Are Differentially Affected by Exclusive Enteral Nutrition
(n=8)




• Ant-TNF’s for complex perianal=4
Study 4 ( 54 completing EEN )
• Early mucosal healing with Exclusive Enteral Nutrition is associated with













1. The	 relative	 importance	 of	 choice	 of	 initial	 induction	 therapy	 and	 early	 use	 Immuno-
modulators	on	medium	term	outcomes	in	paediatric	Crohn’s	disease.	
2. More	specifically,	if	choice	of	EEN	over	corticosteroids	induction	therapy	in	the	setting	of	
















Background:	 Impact	 of	 first-line	 induction	 therapy	 on	 medium-term	 outcomes	 in	 the	 setting	 of	




CD	 and	 follow-up	of	 at	 least	 2	 years	 following	 induction	with	 exclusive	 course	 of	 CS	 or	 EEN	 and	
early,	dose-optimized	TP	(within	6	months	from	diagnosis)	were	evaluated.	We	compared	steroid	
dependency	 (relapse	 within	 3	 months	 of	 tapering	 first	 course	 CS	 or	 inability	 to	 wean	 <10	 mg	


















Crohns	disease	 is	a	chronic,	destructive	 intestinal	disorder	progressing	 in	 the	majority	of	patients	
from	 inflammatory	 behaviour	 to	 complicated,	 stenosing	 and/or	 penetrating	 behaviour.	 Several	





higher	 risks	 of	 surgical	 resection	 (67%-69%)	 (35-36).	 These	 reduced	 surgical	 rates	mirror	 current	
experience	and	presumably	a	 result	of	changing	practices.	There	 is	 reducing	 reliance	on	steroids,	
increased	 use	 of	 Immunomodulators	 and	 biologics	 and	 closer	 patient	 monitoring.	 The	 ultimate	
benefit	 of	 any	 non-curative	 treatment	 for	 CD	 is	 the	 ability	 to	 reduce	 frequency	 and	 severity	 of	
inflammatory	 relapses	 that	 contribute	 to	 long	 term	 cumulative	 bowel	 damage	 and	 these	 are	
increasingly	the	endpoints	against	which	each	treatment	must	be	measured.		
EEN	at	 induction	has	 recently	 superseded	steroids	 in	paediatric	practice	giving	a	more	prolonged	
corticosteroid	free	remission,	fewer	relapses	and	better	linear	growth	(168).		Early	commencement	
of	TP,	within	6	months	of	diagnosis,	has	become	widespread	practice	in	both	adult	and	paediatric	
CD	since	a	 seminal	RCT	 in	 treatment	naïve	children	with	CD	demonstrated	a	greater	 steroid	 free	
remission	 in	 those	 commenced	on	early	 thiopurines	 (97).	Recent	 retrospective	paediatric	 studies	
have	reported	much	lower	efficacy	of	TP	in	maintaining	remission	in	Paediatric	CD.	(53,169-171)	
Similarly,	two	current	adult	controlled	trials	have	concluded	that	early	introduction	of	TP	does	not	
improve	 outcomes	 including	 maintenance	 of	 steroid	 free	 remission,	 need	 for	 anti-TNF	 and	









The	 Brisbane	 Paediatric	 Inflammatory	 Bowel	 Disease	 database	 has	 been	 a	 major	 initiative	 for	
collecting	 IBD	 data	 both	 retrospectively	 and	 prospectively	 since	 2005,	 as	 part	 of	 an	 ethically-
approved	 longitudinal	 audit	of	 the	natural	history	and	genetics	of	CD	and	UC	at	Royal	Children’s	
Hospital	(RCH).			
Brisbane	Paediatric	 IBD	services	was	established	in	2005,	covering	Queensland	population	of	4.78	
million	 in	2014.	 	 IBD	database	only	captured	children	managed	at	Royal	Children’s	Hospital,	state	
tertiary	referral	children’s	hospital.	Children	with	IBD	diagnosed	and	managed	by	private	physicians	









(n=14).	 Phenotype	 data	 including	 patient	 characteristics:	 endoscopy,	 radiology,	 biochemistry,	
concurrent	 treatments	 and	 outcomes	 were	 retrieved	 from	 our	 database,	 medical	 charts	 and	




The	primary	outcomes	of	 interest	were	 steroid	dependency,	CS/IFX	 free	 remission,	 linear	growth	
and	 surgical	 resections	 at	 12	 and	24	months	 following	diagnosis.	 Introduction	of	 TP	 and	 starting	
dose	was	at	the	discretion	of	the	treating	gastroenterologist,	aiming	for	AZA	dose	2–2.5	mg/kg/day	
















abnormalities	 could	 not	 be	 examined.	 	 	 SES-CD	was	 assigned	 based	 on	 consensus	 between	 two	
authors	 after	 reviewing	 images	 and	 endoscopy	 reports.	 Mild,	 Moderate	 and	 severe	 endoscopic	





for	 a	 minimum	 period	 of	 6	 weeks	 as	 described	 previously	 (175).	 Children	 were	 offered	 either	
Nutrison	(1	kcal/ml,	Nutricia	UK,	4	g	protein,	3.9	g	fat/100	ml)	through	nasogastric	tube	(NGT)	or	
resource	 protein	 (1.25	 kcal/ml,	 Nestle,	 9.4	 g	 protein,	 3.5	 g	 fat/	 100	 ml)	 orally	 based	 on	 their	
preference	 and	 dietetic	 consultation.	 Small	 amounts	 of	 clear	 fluids	 and	 jelly	 were	 allowed	
empirically	 and	 concurrently	 to	 improve	 palatability	 and	 those	 struggling	 with	 oral	 EEN	 were	






Calprotectin	 and/or	 endoscopically	 or	 radiologically	 confirmed	 relapse	 after	 successful	 initial	





Pad	 Software,	 San	 Diego,	 CA,	 USA.	 Descriptive	 continuous	 data	 is	 reported	 as	 an	 inter-quartile	
range.	 Baseline	 disease	 characteristics	 including	 age,	 duration	 of	 symptoms,	 CD	 phenotype,	
behaviour,	 severity	and	growth	were	compared	between	EEN	and	Steroids	 induction	group	using	

















During	 the	 first	 year	 after	 primary	 induction	 and	 early	 TP	 56%	 relapsed,	 39%	 requiring	 IFX,	 17%	
became	CS	dependent	and	13%	came	to	surgery.	Choice	of	EEN	over	CS	in	the	setting	of	early	dose	
optimised	TP	use	was	associated	with	 reduction	 in	 linear	growth	 failure	 (7%	vs.	26%,	p=0.02),	CS	
dependency	(7%	vs.	43%,	p=0.002)	and	sustained	primary	response	to	 IFX	 (86%	vs.	68%,	p=0.02).	












Choice	of		first	induction	therapy	 Steroid(n=46)	 EEN	(n=43)	 P	
Age:	Median(IQR)	 11.5(9.5-13)	 13(11.35-14)	 0.004	
Sex:	Male	(%)	 28(61%)	 29(68%)	 0.5	
































































































































Table	 2.2	 Outcomes	 at	 12	 &	 24	 months	 following	 CS	 vs.	 EEN	 induction	 and	 early	 use	 of	
maintenance	TP		






































































































































12	months.	 Reason	 for	 discontinuation	were	 patient	 or	 physician	 discretion	 (n=7),	 bone	marrow	
toxicity	 (n=2),	 persistent	 nausea,	 unexplained	 fevers	 and	 oral	 ulceration	 (n=1)	 and	
pancreatitis/abnormal	 liver	 enzymes	 (n=1).	 TP	 were	 initiated	 within	 3	months	 from	 diagnosis	 in	
64/78	 (82%)	 and	 in	 14/78(18%)	 between	 3-6	months	 Optimal	 6TG	 levels	 (>250	 pmol/8×108	 red	
blood	 cells)	 were	 confirmed	 at	 least	 once	 in	 61/78(78%)	 during	 the	 first	 year	 after	 diagnosis.	 A	
further	56/78	(72%)	patients	continued	TP	beyond	12	months.	TP	was	ceased	during	second	year	
because	of	intolerance	(n=2)	and	physicians	discretion	(n=12).	During	the	second	year	50/56	(89%)	






with	 CD.	Our	 study	 demonstrates	 further	 evidence	 of	 EEN	 superiority	 over	 CS	 in	 reducing	 linear	
growth	 failure	 (7%	 vs.26%,	 p=0.002),	 steroid	 dependency	 (7%	 vs.	 43%,	 p=0.002)	 and	 improving	
sustained	response	to	IFX	(86%	vs.	67%,	p=0.02).		These	benefits	were	seen	despite	the	EEN	group	
having	a	more	severe	phenotype	with	more	extensive	disease	distribution	and	a	higher	clinical	and	
endoscopic	 disease	 activity	 at	 diagnosis.	 	 At	 one	 and	 two	 year	 endpoints,	 CS/IFX	 free	 remission	
rates	favoured	EEN	vs	CS	induction	(49%	vs.39%	at	1	year	and	33%	vs.	24%	at	2	years)	but	not	were	
statistically	different.	Our	results	also	 indicate	that	choice	of	 induction	therapy	did	not	alter	early	






The	 timing,	 duration	 and	 levels	 of	 thiopurines	 did	 not	 have	 any	 influence	 CS/IFX	 free	 remission	
rates	 outcomes	 over	 the	 first	 2	 years	 (data	 not	 shown).	 Previous	 studies	 comparing	 long	 term	
outcomes	after	EEN	vs.	Steroids	have	also	demonstrated	reduced	relapse,	less	steroid	exposure	and	
better	 linear	 growth	 (92-94).	 Lambert	 et	 al	 (94)	 reported	 one	 year	 (61%	 vs.	 77%)	 and	 two-year	
relapse	rate	of	 (61%	vs.	89%)	comparing	EEN	with	Steroids	with	significantly	 less	use	of	 Immuno-
modulators	(26%	vs.	65%)	in	a	paediatric	cohort	where	early	TP	use	was	not	routine.	We	observed	





the	 first	 year	 was	 noted	 after	 EEN	 vs.	 CS	 (46.5%vs.32.5%,	 p=NS),	 this	 is	 again	 a	 reflection	 of	
changing	treatment	paradigms.	
Using	a	definition	of	height	Z	scores	-1.64	as	presence	of	growth	failure,	we	confirm	much	greater	
proportion	 of	 children	 with	 persistent	 growth	 failure	 after	 CS	 induction	 vs.	 EEN	 (17.5%	 vs	 2%,	
p=0.02).	Several	studies	have	reported	better	linear	growth	on	EEN	vs.	Steroids	(88-90),	however	a	









rates	 of	 (39%	 vs.	 51%,	 and	 24%	 vs.	 33%,	 p=NS)	 after	 CS	 vs.	 EEN.	 	 These	 disappointing	 results,	
despite	early	aggressive	TP	usage	are	comparable	 to	a	French	paediatric	 study	evaluating	 role	of	
early	thiopurines	after	CS	(n=31)	and	EEN	(n=42)	reporting	CS/IFX	free	remission	rates	of	39.8%	and	
31.2%	at	1	and	2	years	(170).	






This	 study	 has	 several	 limitations	 including	 its	 retrospective	 nature,	 bias	 of	 changing	 treatment	
paradigms	 with	 time	 and	 lack	 of	 propensity	 score	 matching,	 a	 more	 accurate	 measure	 of	
intervention	in	observational	cohort	studies.	However,	medium	term	benefits	of	choosing	EEN	over	
CS	were	apparent	in	our	study	despite	more	Ileocolonic	disease	at	diagnosis	and	a	higher	baseline	










































METHODS:	 In	a	prospective,	open	 label	 study	34	children	 (Mean	13.1	years;	21	males)	with	new	
diagnosis	 CD	 were	 offered	 EEN,	 26	 completed	 a	 minimum	 6	 weeks	 EEN	 and	 underwent	 paired	
clinical,	biochemical	&	endoscopic	assessment	at	start	and	completion	using	PCDAI,	BMI,	CRP	and	





p<.001)	 and	 MRE	 (5.14	 to	 2.79,	 p=.01).	 22/26	 (84%)	 achieved	 clinical	 remission;	 20	 (76%)	
biochemical	 remission.	 15	 (58%)	 had	 early	 good	 endoscopic	 response,	 (11	 complete	 MH	 (SES-
CD=0),	 4	 near	 complete	MH,	 SES-CD	 ,1-3)	 and	 3/14	 (21%)	 had	 transmural	 remission	 of	 Ileal	 CD	
(MRE-CD:	0-1).	Early	good	endoscopic	response	was	associated	with	reduced	endoscopic	confirmed	
relapse	 (53%	 vs.	 100%,	 p=0.02),	 anti	 TNF	 use	 (33%	 vs.88%,	 p=0.01)	 and	 hospitalisation	 (40%	 vs.	
88%)	at	1	year.			










employment	 and	 nearly	 25%	 of	 patients	 are	 diagnosed	 before	 16	 years	 of	 age	 (158).	 Paediatric	
onset	 Crohn’s	 disease	 is	 a	 more	 severe	 phenotype	 with	 the	 additional	 issues	 of	 growth	 failure,	
delayed	puberty,	poor	bone	density	and	the	consequences	of	a	chronic	disease	commencing	at	a	
vulnerable	 period	 of	 psychosocial	 development	 (42-51).	 Cohort	 studies	 comparing	 the	 clinical	




as	 an	 important	 end	 point	which,	when	 achieved	 in	 the	 first	 year,	 leads	 to	 less	 frequent	 clinical	
relapses,	fewer	hospitalisations,	reduced	surgical	resections	and	lower	risk	of	fistulising	disease	(6-
7,152).	
Treatments	 for	 induction	 of	 remission	 in	 CD	 include	 corticosteroids,	 EEN	 (exclusive	 enteral	
nutrition)	 and	 biologic	 agents.	 For	 clinical-remission	 high	 quality	 studies	 and	 those	 in	 paediatric	
cohorts	comparing	steroids	and	EEN	show	them	to	be	equally	effective	in	up	to	80%	of	patients	(9).	
However;	clinical	remission	indicated	by	improved	symptom	control	alone	is	inadequate.	Not	only	
is	mucosal	disease	active	 in	 the	majority	of	asymptomatic	patients	 treated	with	steroids	 (10)	but	
treatment	 to	 this	 endpoint	 over	 the	 past	 20	 years	 has	 failed	 to	 avert	 the	 progressive	 and	
complicated	course	of	CD	(5),	particularly	in	children.	Our	hypothesis	was	that	EEN	induces	superior	












parents.	 This	 study	 was	 retrospectively	 registered	 with	 ANZ	 clinical	 trials	 registry	 -
ACTRN12612001032842	in	September	2012.		
The	 diagnosis	 of	 CD	 was	 based	 on	 established	 clinical,	 endoscopic,	 histological	 and	 radiological	
criteria.	All	new	diagnoses	of	CD	were	offered	EEN	as	the	preferred	first	line	therapy,	those	electing	
for	CS	as	a	sole	induction	therapy	were	not	eligible	for	the	trial.		Other	exclusions	criteria	included:	
stricturing	 disease	 with	 proximal	 bowel	 dilatation	 and	 obstructive	 symptoms;	 previous	 or	
concurrent	 use	 of	 steroids,	 thiopurines	 or	 biological	 agents	 for	 indication	 other	 than	 luminal	 CD	
(example	 autoimmune	 hepatitis	 or	 Juvenile	 idiopathic	 arthritis);	 inability	 to	 tolerate	 oral	 or	
Nasogastric	(NG)	tube	EEN	for	a	minimum	of	6	weeks.	
All	 enrolled	patients	underwent	 comprehensive	assessment	 including	PCDAI,	 growth	parameters,	
CRP,	Endoscopy	at	diagnosis	and	8	weeks.	Children	were	offered	either	Nutrison	(1Kcal/ml,	Nutricia	
UK,	 40g	 Protein,	 39	 g	 Fat	 /1000ml)	 through	 Nasogastric	 tube	 (NGT)	 or	 Resource	 protein	
(1.25Kcal/ml,	Nestle,	 18.8g	 Protein,	 7g	 Fat	 /200ml)	 orally	 based	on	 their	 preference	 and	dietetic	
consultation.	 The	 prescribed	 volumes	were	 based	 on	 Schofield’s	 equation	which	 predicts	 resting	
energy	expenditure	 (180).	 	Feeds	were	gradually	 increased	to	 target	volumes	 in	3	 to	5	days.	 	For	




and	 Jelly	were	 allowed	 empirically	 and	 concurrently	 to	 improve	 palatability	 and	 those	 struggling	
with	oral	EEN	were	allowed	to	add	small	amounts	of	flavouring	or	change	to	NG	route.	To	maximise	
compliance	 with	 EEN,	 clinical	 and	 dietetic	 staff	 provided	 support	 with	 regular	 phone	 calls	 and	
outpatient	visits.	After	completion	of	EEN	and	during	remission	phase	no	dietary	restrictions	were	
recommended.	
Primary	 end	 points	 of	 the	 study	 were	 to	 determine	 efficacy	 of	 EEN	 for	 inducing	 early	 clinical,	
biochemical,	mucosal	 and	 transmural	 remission	 at	 8	weeks.	 Secondary	 outcomes	were	 to	 relate	
early	 endoscopic	 response	 to	 subsequent	 clinical	 outcomes,	 specifically	 endoscopic	 confirmed	
relapse,	CD	related	hospitalisation,	need	to	commence	biological	agent	and	surgical	resection	at	1	
year.		
It	 is	our	practise	 to	 commence	Thiopurines	 (Azathioprine	or	6-Mercaptopurine)	during	or	 shortly	
after	EEN	induction	therapy	based	on	the	Markowitz	publication	confirming	lower	clinical	relapse	in	
children	 with	 early	 introduction	 of	 6-MP	 after	 steroid	 induction	 therapy	 (97).	 Time	 to	 initiate	
thiopurines	was	 at	 the	 discretion	 of	 the	 treating	 gastroenterologist.	 All	 children	were	 eventually	
commenced	on	Thiopurines	within	3	months	of	 their	 initial	diagnosis	aiming	 for	2-2.5mg/kg/day,	
modified	according	to	TPMT	status	and	drug	monitoring,	6-TG	levels	>250pmol/8×108	erythrocytes.		
Current	 Australian	 Pharmaceutical	 Benefits	 Scheme	 (PBS)	 criteria	 in	 children	 restrict	 use	 of	
infliximab	to	those	with;	complex	perianal	fistulising	disease	or	active	clinical	/endoscopic	disease	
after	 a	 minimum	 8	 weeks	 EEN	 or	 steroids	 and	 3	 months	 conventional	 Immunomodulator	









Classification	 was	 based	 on	 previously	 published	 modified	 Montreal/Paris	 classification	 (158);	
presence	of	growth	failure	was	defined	as	(Z	score	-1.64	corresponding	to	<5	th	percentile)	as	G1,	




otherwise	 normal	 appearing	 mucosa	 was	 disregarded	 for	 the	 purpose	 of	 disease	 classification	
(158).	Extensive	 intestinal	 involvement	was	classified	as	 Ileocolonic	and	Upper	GI	(L3+L4)	disease.	
Small	Bowel	CD	out	of	reach	of	endoscopy	was	defined	using	standard	MR	Enterography	criteria;	
Bowel	wall	thickness	>3	mm,	contrast	transmural	enhancement,	skip	lesions,	Stricturing	/	fistulising	
disease	plus	other	 supportive	 features	 like	 fibro-fatty	proliferation,	mesenteric	 lymphadenopathy	
and	comb	sign	(159).		
Clinical	and	biochemical	disease	activity	
Clinical	 remission	 was	 defined	 as	 PCDAI<10;	 Biochemical	 remission,	 CRP<5	 mg/L	 with	
PCDAI<10(161,	 175,184).	 Relapse	 was	 defined	 as	 PCDAI>15	 on	more	 than	 one	 occasion	 1	 week	
apart	 and	or	CRP>5mg/L	with	 clinically	 active	disease.	A	PCDAI	>30	was	 considered	moderate	 to	
severe	Paediatric	CD.	(161)	
Mucosal	Disease	Activity	














Previously	 validated	 MRI	 disease	 activity	 scores	 were	 applied	 to	 each	 MRE	 by	 an	 experienced	
Radiologist,	blinded	to	endoscopy	reports,	to	determine	transmural	disease	activity	of	small	bowel.	






range.	 Baseline	 disease	 characteristics	 including	 CD	 phenotype,	 behaviour,	 severity,	 time	 to	











Forty-two	 patients	 were	 diagnosed	 with	 CD	 during	 the	 study	 period,	 eight	 preferred	 steroid	
induction	therapy).	34	children	were	eligible	for	the	trial	and	8	excluded:	2	received	concurrent	anti	








route	 alone,	 14/26(54%)	 received	 EEN	 via	NG	 tube	 because	 of	 palatability,	 inadequate	 intake	 or	
poor	 compliance.	 Follow	 up	 Colonoscopy	 with	 Ileal	 intubation	 was	 successful	 in	 all	 except	 one	
where	 Ileal	 stricture	precluded	 intubation.	Baseline	disease	phenotype	of	 the	26	eligible	 children	
was:	Median	age	13.1	years	(9.5-15.75	IQR),	19	Males;	Ileocolonic	disease	in	21	(80%),	Stricturing	8	
(31%,	 which	 includes	 1	 penetrating	 and	 4	 Perianal	 disease	 (15%).	 	 At	 diagnosis:	 clinical	 disease	
activity	 was	 moderate	 to	 severe,	 PCADI	 >30	 in	 23	 (88%);	 endoscopic	 disease	 activity	 was	 mod-
severe	SES-CD>10	 in	22	(84%);	MRE	was	active	 in	24/26	(92%)	children	at	diagnosis:	moderate	to	






obstructive	 symptoms	 associated	 with	 proximal	 dilatation	 on	 MR	 Enterography	 and	 went	 to	






































































Patient	Characteristics	 Before	EEN	 After	EEN	 P	Value	
Mean	Weight	Z	score	(n=26)	 -0.79	 -0.08	 0.03	
Mean	Height	Z	score(n=26)	 -0.19	 -0.005	 NS	
Mean	BMI	Z	Score(n=26)	 -1.40	 -0.54	 <0.01	
Mean	PCDAI(n=26)	 37.88	 7.01	 <0.001	
Mean	CRP(n=26)	 44.86	 5.5	 <0.001	
Mean	SES-CD(n=26)	 14.28	 3.88	 <0.001	
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22/26	 (84%)	 were	 in	 clinical	 remission;	 20/26	 (76%)	 in	 both	 biochemical	 and	 clinical	 remission;	
11/26	(42%)	children	had	complete	mucosal	healing	(SES=0);	4/26	(16%)	near	complete	healing	(SES	
1-3)	 to	 give	 an	 early	 good	 endoscopic	 response	 rate	 of	 58%;	 8/26	 (30%)	 improved	 but	 had	
























































	 Early	TP	(n=16)	 Later	TP(n=10)	 Significance	
Mean	PCDAI	 39.06	 36	 0.20	
Mean	BMI	 -1.5	 -1.37	 0.8	
Mean	CRP	(mg/L)	 56.19	 26.10	 0.1	
Mean	SES-CD	 15.6	 12.3	 0.1	
Pan-enteric	disease	(Ileocolonic+UGI)	 11/16(68%)	 10/10(100%)	 0.12	
Complicating	disease	 4/16(25%)	 4/10(40%)	 0.6	




Outcomes	at	1	year,	n=24	 Early	TP	(n=15)	 Subsequent	TP(n=9)	 P	value	
Endoscopic	Relapse	(n=17)	 10	 7	 0.6	
Hospitalisation	at	follow	up	(n=14)	 8	 6	 0.6	
Anti-TNF	use	(n=13)	 8	 5	 1	






Subsequent	 clinical	 outcomes,	 specifically	 endoscopic	 confirmed	 clinical	 relapse,	 hospitalisation	
directly	related	to	CD,	need	to	commence	anti-TNF	agent	and	surgical	resection	were	analysed	at	1	
year	 (n=24/26).	 Early	 good	endoscopic	 response	 led	 to	decreased;	 endoscopic	 confirmed	 relapse	
(8/15,53%	vs.	9/9,100%,	p=0.02),	hospitalisation	(6/15,40%	vs.	8/9,	88%,	p=0.03),	need	for	anti	TNF	




Complicating	 (Stricturing	 and/or	 fistulising)	 vs.	 Inflammatory	 phenotype	 at	 diagnosis	 was	 more	
frequently	associated	with	moderate	to	severely	poor	BMI	Z	score	<	 -2.0	 in	5/8	vs.	3/16	(p<0.01)	
and	longer	duration	of	symptoms	before	diagnosis	(mean	12.15	vs.	5.47	months	p<0.02).	7/8	of	our	
cohort	 with	 non-obstructive	 stricturing	 at	 presentation	 required	 surgical	 resection	 despite	
improvement	in	mucosal	disease	severity	(Mean	SES	14.38	at	diagnosis	to	Mean	SES	5.50	post	EEN,	
p<0.05)	 and	 BMI	 recovery	 (Mean	 Z	 score	 -1.72	 at	 diagnosis	 to	 -0.76,	 p>0.05).	 Good	 endoscopic	
response	was	only	observed	in	3/8	complicating	disease	(SES-CD=3),	confirming	the	impression	EEN	












six-week	 course	 of	 EEN	 and	 12	 completed	 weaning	 course	 of	 CS	 over	 8-10	 week’s	 (Figure	 3.4).	
Relapse	during	first	year	requiring	anti-TNF’s	was	similar	between	EEN	(13/26,50%)	and	CS	group	















• Infliximab for complex perianal CD=2
CS (n=4)
• Auto-immune hepatitis (n=1)
• Erythema Nodosom (n=1)
• Did not tolerate EEN (n=2)
EEN (26 finished 6 weeks course
Outcomes
Outcome of EEN group at 1 year (n=26)
Therapies at 1 year
• TP monotherapy =13
• Anti-TNF’s
• Anti-TNF’s + TP=7
• Anti-TNF’s+ Methotrexate= 3
• Anti-TNF’s=3
Intestinal resection =7/26 (27%)
Outcome of CS group at 1 year (n=12)
Therapies at 1 year
• TP monotherapy = 5
• Anti-TNF’s
• Anti-TNF’s +TP=4
• Anti-TNF’s+ Methotrexate= 2
• Anti-TNF’s=1




This	 study	 is	 the	 first	 to	 comprehensively	 and	 prospectively	 address	 the	 early	 impact	 of	 EEN	 on	
clinical,	biochemical,	endoscopic	and	MRE	parameters	in	children	with	moderate	to	severe	CD.		EEN	
gives	excellent	early	clinical	response,	weight	recovery,	biochemical	remission	and	mucosal	healing.	
This	 study	 is	 also	 the	 first	 to	 evaluate	 the	 impact	 of	 EEN	 induced	 early	 mucosal	 healing	 on	
subsequent	medium	term	outcomes	in	children	receiving	maintenance	therapy	with	thiopurines.	
EEN	 is	 highly	 effective	 for	 the	 induction	 of	 disease	 remission	 exceeding	most	 currently	 reported	
treatment	endpoints,	providing	complete	mucosal	healing	in	over	40%	of	children	and	transmural	
remission	of	 small	 bowel	 CD	 in	 (3/14,	 21%).	 Previous	 trials	with	 EEN	used	 variable	definitions	of	
mucosal	healing	but	we	chose	a	more	rigorous,	simpler	endpoint,	that	of	complete	mucosal	healing	
(complete	disappearance	of	Ileocolonic	ulceration)	to	provide	compelling	evidence	of	efficacy.	We	
also	 demonstrated	 improved	 transmural	 disease	 activity	 in	 those	 with	 Ileal	 or	 Ileocolonic	 CD	
utilising	MR	Enterography	in	a	subset	of	children.		
Our	early	mucosal	healing	rates	are	comparable	to	other	trials	of	EEN.	 	A	single	Paediatric	RCT	 in	
newly	 diagnosed	 children	 with	 CD	 comparing	 EEN	 vs.	 steroids	 demonstrated	 EEN	 to	 give	
endoscopic	 remission	 (using	 CD-EIS)	 of	 74%	 at	 10	 weeks,	 comparable	 to	 our	 more	 rigorous	
definition	of	good	endoscopic	response	(SES-CD<3)	of	58%(10).	In	treatment	naïve	adults	with	CD,	
EEN	 gave	 complete	 endoscopic	 remission	 rate	 of	 44%	 at	 terminal	 ileum	 and	 39%	 in	 colon	 at	 4	
weeks	(12).		In	contrast,	our	study	showed	higher	but	non-significant	good	endoscopic	response	in	
colonic	vs.	 Ileal	disease	segments	 (61.5%	vs.53.8%,	p>0.05).	 	Both	studies	were	underpowered	to	
discriminate	 a	 difference	 but	 consistent	 with	 a	 recent	 study	 and	 systematic	 analysis	 which	
concluded	disease	phenotype	does	not	influence	EEN	induced	clinical	remission	rates	(65,75).		
These	well	 characterized	 outcomes	 specifically	 early	mucosal	 healing	 compare	 favorably	with	 all	










endoscopic	 recovery	 and	 1	 year	 outcomes	 including	 endoscopic	 relapse,	 anti-TNF	 use,	
hospitalisation	and	intestinal	resection	were	comparable	between	early	vs.	 late	TP	use.	Our	study	
was	although	not	appropriately	powered	or	designed	to	address	short	and	medium	term	benefits	
of	early	vs.	 later	 IM	use.	Most	 children	commenced	TP	after	4	weeks	of	EEN	 to	optimise	patient	
vaccination	 status	 and	 the	 delayed	 peak	 efficacy	meant	 use	 or	 otherwise	 was	 unlikely	 to	 affect	
clinical,	 biochemical	 and	 endoscopic	 outcomes	 less	 than	 4	 weeks	 later.	 There	 are	 no	 published	
studies	looking	at	mucosal	healing	before	16	weeks	of	immunomodulator	treatment	(144-148).	
Our	 small	 EEN	 study	 cohort	 presented	with	 a	 high	 proportion	 of	 complicated	 phenotypes	 (8/26,	
31%)	 and	 this	 is	 reflected	with	 the	 high	 rate	 of	 adverse	 longer	 term	outcomes	 despite	 excellent	
early	 clinical	 response.	At	1	year,	17/24,	 (71%)	had	 relapsed;	13/24,	 (54%)	commenced	anti-TNF;	
14/24	(58%)	had	been	hospitalised	and	7/24	(29%)	had	surgical	resection.		A	non-significant	higher	
frequency	of	 complicated	disease	phenotype	at	diagnosis	was	observed	 in	 those	 included	 in	EEN	
study	 (8/26	 ,31%)	compared	to	32/183	 (17.5%,	P=0.11)	 in	our	Brisbane	 IBD	historical	cohort	 (not	
published).	This	could	be	partially	explained	by	availability	of	MR-Enterography	from	2009,	enabling	
improved	detection	of	complicating	phenotype	in	cohort	diagnosed	after	2009.		
	A	 recent	 French	 paediatric	 Cohort	 study	 reported	 complicating	 disease	 rates	 of	 28%	 at	





in	50%,	confirming	EEN	works	best	 for	patients	with	 inflammatory	phenotype.	Even	 in	Stricturing	
patients,	 EEN	 corrected	 poor	 nutrition	 and	 improved	 clinical	 status	 in	 preparation	 for	 successful	
surgery.		
We	 confirmed	 superior	 outcomes	 at	 1	 year	 in	 those	 with	 early	 good	 endoscopic	 response	 with	
reduced;	endoscopic	confirmed	clinical	relapses	(8/15,	53%	vs.	9/9,	100%,	p=0.02),	hospitalisation	
(6/15,40%	vs.	8/9,88%,	p=0.03);	and	need	for	anti-TNF	for	luminal	disease	(5/15,33%	vs.	8/9,88%,	
p=0.01).	 	 Our	 finding	 that	 early	 mucosal	 healing	 from	 EEN	 may	 be	 more	 important	 than	 early	
introduction	of	TP	for	improving	subsequent	clinical	outcomes	has	support.	In	a	placebo	controlled	
RCT	 with	 adalimumab	 in	 adults	 with	 moderate	 to	 severe	 CD	 the	 importance	 of	 early	 mucosal	
healing	was	demonstrated	with	a	positive	of	predictive	effect	of	early	(12	week)	mucosal	healing	on	
CDAI	at	52	weeks	(164).	 	Earlier	azathioprine	therapy	vs	 later,	“on	demand”	azathioprine	was	not	









regardless	 of	 initial	 choice	 of	 EEN	 vs.	 CS,	 although	 our	 study	 was	 not	 powered	 to	 address	 this	




over	 CS	 in	 children	 presenting	 with	 complicating	 disease	 phenotype	 at	 diagnosis.	 A	 rapid	
therapeutic	escalation	to	anti-TNF’s	was	noted	in	the	entire	cohort	with	over	half	of	them	(20/38,	
53%)	on	anti-TNF	within	 the	 first	 year	 (13/24,	 EEN	vs.	 7/12,	CS	group).	 This	 reflects	 again	newer	
treatment	paradigms	aiming	for	CS	free	endoscopic	remission.	
As	outlined	above,	there	are	number	of	 limitations	of	our	study	 including	size,	open	 label	design,	
and	 lack	of	 centralised	endoscopy	 reading	 and	unavailability	of	 paired	endoscopic	 assessment	of	
those	treated	with	CS.		
In	conclusion,	CD	in	children	is	recognised	as	a	more	aggressive	phenotype	than	in	adults	and	needs	
improved	 treatment	 endpoints.	 	 We	 demonstrate	 EEN	 to	 be	 highly	 effective	 for	 inducing	 early	
endoscopic	and	transmural	healing	in	treatment	naive	children	with	moderate	to	severe	CD.		Early	
mucosal	healing	with	EEN	and	thiopurines	does	not	prevent	most	children	with	Stricturing	disease	








































Background:	 	 	Mucosal	Healing	 (MH)	 is	 a	 vital	 early	endpoint	 in	management	of	Crohn’s	disease	
(CD).	 MH	 depends	 on	 endoscopic	 assessment	 and	 there	 is	 increasing	 interest	 in	 non-invasive	





and	 after	 eight	weeks	 therapy	with	 EEN	 or	 steroids.	 The	 purpose	 of	 our	 study	was	 to	 correlate	
disease	 proxies	 (PCDAI,	 CRP,	 FC)	 with	 simple	 endoscopic	 score	 (SES-CD)	 at	 diagnosis	 and	 assess	
their	performance	in	predicting	endoscopic	disease	scores	after	primary	induction	therapy	with	EEN	
or	steroids.		




















standard	for	assessing	mucosal	 inflammation	is	endoscopy,	but	this	 is	 invasive	and	impractical	for	
regular	monitoring	which	requires	studies	to	use	surrogate	markers,	proxies	like	CDAI,	PCDAI,	CRP	
and	 Faecal	 Calprotectin	 (FC),	 to	 assess	 therapeutic	 response.	 This	 is	 of	 particular	 concern	 when	
non-invasive	 proxies	 like	 CDAI	 and	 PCDAI	 are	 used	 to	 determine	 treatment	 escalation	 and	 as	
endpoints	for	research	outcomes.			
Poor	concordance	between	clinical	disease	activity	index	(CDAI)	and	endoscopic	disease	activity	is	
well	 established	 in	 adults	with	 active	 CD	with	 up	 to	 70%	 of	 patients	 in	 clinical	 remission	 having	
significant	 mucosal	 lesions.	 (10,138)	 The	 Paediatric	 Crohn’s	 Disease	 activity	 Index	 (PCDAI)	 is	 a	
clinical	 tool	 like	 CDAI,	 that	 includes	 subjective	 variables	 and,	 unlike	 CDAI,	 PCDAI	 has	 not	 been	
validated	against	established	endoscopic	disease	activity	scores.	
Serum	CRP	and	Faecal	Calprotectin	 (FC)	 are	 in	widespread	use	as	proxies	 for	endoscopic	disease	
activity.		In	a	prospective	adult	endoscopic	study,	CRP	(r=0.53)	and	FC	(r=0.75)	had	good	correlation	
with	 simple	 endoscopic	 disease	 activity	 scores	 (SES-CD)	 (142).	 In	 a	 small	 paediatric	 study,	 good	







A	 paediatric	 Finnish	 study	 treating	 children	 with	 IBD	 to	 clinical	 remission	 with	 steroids	 and	 a	
Scottish	 study	 treating	 children	 with	 CD	 to	 clinical	 remission	 with	 EEN	 showed	 the	 majority	 of	
children	in	clinical	remission	had	elevated	FC.	(105,107)	
Paediatric	 studies	 evaluating	 performance	 of	 PCDAI,	 CRP	 and	 FC	 against	 a	 validated	 endoscopic	
disease	activity	tool	to	measure	therapeutic	response	are	warranted.		The	purpose	of	our	study	was	






This	 study	 cohort	 is	 an	 extension	 of	 our	 previously	 described	 prospective	 study	 (Australia	 New	
Zealand	Clinical	 Trails	 Registry-	ACTRN12612001032842)	 of	 42	newly	diagnosed	 children	with	CD	
(<16	years)	offered	EEN	or	steroids	as	induction	therapy	and	commenced	on	early	thiopurines	(<3	
months)	 conducted	between	November	2009	 to	December	2013	 in	a	 tertiary	paediatric	hospital.	
(174)	 Institutional	 Ethics	 approval	 was	 granted	 and	written	 consent	 obtained	 from	 patients	 and	
parents.	 Convenience	 sample	 of	 24	 children	who	 had	 luminal	 CD	 quantifiable	 on	 complete	 Ileo-
colonoscopy	and	paired	PCDAI,	CRP,	FC	and	Endoscopy	at	diagnosis	and	after	8	weeks	of	induction	















CD)	 with	 clinical,	 serologic	 and	 faecal	 biomarkers	 was	 estimated	 using	 the	 non-parametric	
Spearman	rank	correlation	coefficient.		Paired	t	test	was	used	for	analysis	of	proxies	before	&	after	






in	 24	 children	 treated	with	either	 EEN	 (n=20)	or	 steroids	 (n=4)	 at	 diagnosis.	 Baseline	 results	 and	


















































































PCDAI	 CRP	 FC	 SES-CD	 PCDAI	 CRP	 FC	 SES-CD		
1	(EEN)	 32.5	 17	 1300	 4	 20	 5	 620	 0	
2	(EEN)	 40	 42	 1100	 15	 5	 1	 70	 0	
3	(EEN)	 35	 24	 470	 11	 10	 4	 950	 0	
4	(EEN)	 47.5	 19	 1300	 25	 5	 1	 280	 0	
5	(EEN)	 35	 20	 510	 8	 0	 1	 170	 0	
6	(EEN)	 35	 14	 1100	 15	 5	 2	 480	 0	
7	CS	 42.5	 54	 460	 22	 5	 2.7	 330	 0	
8	(EEN)	 17.5	 71	 1200	 18	 0	 1	 420	 0	
9	(EEN)	 32.5	 23	 1800	 21	 0	 1	 180	 0	
10	(EEN)	 45	 29	 580	 18	 30	 8	 170	 0	
11(EEN)	 32.5	 22	 1300	 13	 0	 2.7	 380	 2	
12.(EEN)	 47.5	 100	 240	 15	 10	 28	 450	 3	
13	CS	 37.5	 34	 240	 12	 5	 7	 1300	 3	
14	(EEN)	 42.5	 11	 550	 9	 5	 1	 1000	 3	
15(EEN)	 32.5	 43	 800	 12	 5	 1	 220	 4	
16(EEN)	 47.5	 13	 410	 12	 5	 1	 220	 4	
17(EEN)	 32.5	 10	 580	 12	 10	 5	 100	 6	
18(EEN)	 32.5	 59	 500	 23	 10	 30	 300	 7	
19	CS	 37.5	 17	 1800	 18	 15	 4.5	 580	 8	
20(EEN)	 37.5	 138	 2200	 32	 15	 4.5	 900	 8	
21(EEN)	 57.5	 19	 600	 18	 5	 6	 930	 9	
22(EEN)	 60	 78	 1400	 30	 30	 5	 1400	 12	
23(EEN)	 55	 72	 1900	 17	 10	 1	 1500	 13	

















Diagnosis	 	 	 	 	 	 	 	 	 Post	 Induction	 	 	 	 	 P	
value	
Active	Endoscopic	Disease	(SES-CD	≥3)																




35.9	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 7.27																												
(0.0001)	
(30.4-41.3)								(0.84-13.7)																	





30.45	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 2.67																													
(0.0005)	
(18.4-42.5)									(1.1-4.1)	





1010	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 368																														
(0.003)	
(713-1308)								(199-536)	





15.45	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 0.18																															
(0.0001)	
(11.2-19.6)							(	-0.22-0.5)	














Mean	(SD)	 Ileal		 Ileo-Colonic	 P	Value	







	 Sensitivity	 Specificity	 Positive	LR	 Negative	LR	
Clinical	remission	=CR	(PCDAI≤10)	 47%	 60%	 1.1	 0.8	
Biochemical	remission=BR	(PCDAI≤10,CRP<5)	 64%	 80%	 3.2	 0.4	
Faecal	Calprotectin(FC)	<200		µgm/gm		 80%	 63%	 2.3	 0.3	
FC	<500	µgm/gm	 64%	 80%	 3.2	 0.4	
FC	>50%	drop	from	diagnosis	 69%	 82%	 3.8	 0.38	
BR	&	FC	,	FC	<500	µgm/gm	 82%	 85%	 5.3	 0.2	
	
Table	 4.6	 Pre	&	 Post	 EEN	 induction	 biomarker	 response	 to	 predict	 endoscopic	 remission	 (SES-
CD<3)		
	 Sensitivity	 Specificity	 Positive	LR	 Negative	LR	
FC	<500	µgm/gm	 61%	 71%	 2.1	 0.5	
FC	>50%	drop	from	diagnosis	 73%	 78%	 3.2	 0.35	











































Overall	 therapeutic	response	after	therapy	 include:	clinical	remission	(PCDAI	<10)	 in	19/24	(79%),	
biochemical/clinical	 remission	 (PCDAI≤10	 and	 CRP	 <5mg/dL)	 in	 16/24	 (65%)	 and	 endoscopic	
remission	(inactive	disease	SES-CD	0-2)	in	11/24(46%).			
The	performances	of	PCDAI,	CRP	and	FC	against	SES-CD	are	given	in	Figures	4.4-4.6.		Highlighted	is	
the	 poor	 correlation	 of	 PCDAI	 (r=0.34,	 p=NS)	 and	 CRP	 (r=0.28,	 p=NS)	 with	 SES-CD.	 	 Of	 the	 13	
children	with	active	endoscopic	disease	post	induction,	10	(77%)	were	in	clinical	remission	(PCDAI	
≤10),	 5	 (38%)	 were	 in	 clinical	 and	 biochemical	 remission.	 FC	 (r=0.50,	 p=0.01)	 had	 a	 moderate	
correlation	with	SES-CD	and	only	1	child	(8%)	with	active	disease	had	a	normal	FC	(<200	µgram/gm	
of	 stool).	 However,	 7/11	 (63%)	 children	 with	 inactive	 endoscopic	 disease	 post	 induction	 had	
persistent	 FC	 >200	 µgram/gm.	 These	 patients	 with	 persisting	 FC>200	 with	 inactive	 endoscopic	
disease	had	no	evidence	of	proximal	small	bowel	disease	on	MRE	at	diagnosis	and	2/7	had	a	normal	











NLR	 0.2	 compared	 to	 other	 proxies	 (Table	 4.5).	 Further	 appraisal	 of	 FC	 in	 predicting	 endoscopic	
remission	post	EEN	induction	revealed	73%	sensitivity	and	78%	specificity	for	>	50%	drop	in	FC.	A	




Crohn’s	 disease	 we	 demonstrate	 that	 PCDAI	 is	 a	 poor	marker	 of	 endoscopic	 disease	 severity	 at	
diagnosis	and	a	poor	predictor	of	endoscopic	 treatment	 success.	We	confirm	 findings	 from	adult	
studies	 that	 demonstrate	 CRP	 and	 Faecal	 Calprotectin	 (FC)	 to	 be	 the	 current	 best	 non-invasive	
markers	of	endoscopic	disease	 severity	at	presentation.	We	also	demonstrate	FC	 to	be	 the	most	
reliable	 proxy	 for	 predicting	 good	 endoscopic	 outcomes	 after	 induction	 therapies	 and	 to	 inform	
follow	up.	 	We	confirm	 reports	 that	a	post	 induction	cut	off	 FC<200	µgram/gm	 is	 less	 reliable	 in	
children	 as	many	 children	with	 clinical,	 biochemical	 and	 endoscopic	 remission	will	 have	 FC	 >200	
µgram/gm.		We	report	the	novel	findings	that	FC	drop>50%	after	induction	therapy	provides	much	
greater	 reliability	 for	predicting	 inactive	disease	 than	FC<200	µgram/gm	and	 that	a	 composite	of	






criteria	 and	 therapeutic	 outcome	 with	 almost	 50%	 of	 patients	 treated	 with	 biologics	 in	 clinical	
remission	 had	 active	 endoscopic	 or	 biochemical	 evidence	 of	 residual	 disease	 activity	 (151,189).	
Clinical	 improvement	 is	 important	 for	 quality	 of	 life	 but	 is	 an	 unreliable	 marker	 of	 endoscopic	
disease	severity	and	should	not	be	used	to	assess	endoscopic	severity,	treatment	outcomes	or	the	
performance	 of	 newer	 non-invasive	 proxies.	We	 have	 now	 confirmed	 that	 the	 paediatric	 clinical	
tool,	 PCDAI	 should	 also	 no	 longer	 be	 used	 as	 a	 determinant	 of	 disease	 severity,	 nor	 informing	
treatment	escalation	 strategies	nor	 a	major	 endpoint	 to	determine	 treatment	 success,	 either	 for	
clinical	or	research	purposes.	
CRP	is	superior	to	PCDAI	and	CDAI	as	a	non-invasive	proxy	of	intestinal	inflammation	particularly	at	
diagnosis	 and	 for	 monitoring	 progress.	 Normalisation	 of	 the	 CRP	 is	 a	 common	 and	 important	
therapeutic	outcome.	 	However,	 in	our	 cohort,	 almost	60%	of	 children	with	normalised	CRP	and	
clinical	 remission	 still	 had	 active	 endoscopic	 lesions	 and	 so	 alone,	 a	 fall	 in	 CRP	 at	 8	 weeks	 is	
insufficient	reassurance	of	endoscopic	recovery.	
The	 correlation	 between	 endoscopic	 disease	 activity	 and	 FC	 has	 been	 well	 studied	 in	 adult	
populations	 and	 ranges	 from	 moderate	 to	 good,	 0.35-0.72(180,183,184).	 In	 a	 small	 paediatric	


















While	FC	 cut	off	<200	 is	not	appropriate	 in	 the	paediatric	population,	an	absolute	 cut	off	of	500	
provides	greater	specificity.		Of	greater	interest	is	the	finding	that	a	dynamic	change	in	FC,	a	drop	
>50%	from	diagnosis	has	an	excellent	reliability	for	predicting	inactive	disease.		The	combination	of	
clinical	 and	 FC	 proxies	 to	 accurately	 predict	 endoscopic	 disease	 inactivity	 has	 been	 previously	
reported	 in	 adult	 studies	with	 combined	CDAI,	 CRP	 and	 Faecal	 biomarkers	 having	 sensitivity	 and	
specificity	of	79%	and	70%	(190).	Another	adult	study	combined	FC	and	HBI	to	give	sensitivity	86%	
and	 specificity	 of	 86%	&	 82%	 for	 inactive	mucosal	 disease	 (187).	Using	 PCDAI,	 CRP	 and	 FC	 <500	
μg/gm	we	confirmed	a	sensitivity	of	82%	and	Specificity	of	85%	with	PLR	5.3	and	NLR	0.2.		
One	of	the	major	drawbacks	of	our	study	is	convenience	sample	selection	and	lack	of	paired	MRE.	It	
is	 unclear	 if	 transmural	 and	 histological	 inflammation	 was	 persistent	 in	 children	 demonstrating	










management	 of	 patients	 with	 CD	 and	 for	 the	 assessment	 of	 new	 treatments.	 	 In	 a	 well	
characterised	 cohort	of	 children	with	CD	we	have	demonstrated	 that	PCDAI	 is	unreliable	 for	 this	
purpose,	 CRP	 has	moderate	 utility	 and	 FC	 has	 the	 best	 individual	 utility.	 	 FC	 drop	 >50%	 is	more	



















































Aims	&	Methods:	 	We	 prospectively	 followed	 an	 Australian	 cohort	 of	 newly	 diagnosed	 children	
with	 predominantly	 luminal	 CD	 who	 completed	 at	 least	 six	 weeks	 EEN	 and	 with	 paired	 clinical	
(PCDAI),	biochemical	(CRP)	and	endoscopic	assessment	at	diagnosis	and	post	EEN.	All	commenced	
Immuno-modulators	 (IM’s)	early	 (<3	months	 from	diagnosis)	and	had	minimum	1	year	 follow	up.	
Our	primary	aim	was	to	 investigate	longitudinal	outcomes	of	EEN	treated	patients	based	on	early	






observed	 in	 45/54	 (83%),	 BR	 (PCDAI<10	 and	 CRP<5mg/dl)	 in	 39/54	 (72%).	 Complete	 MH	 was	
observed	 in	18/54	 (33%),	near	complete	 in	10/54(19%).	 	SR	was	superior	 in	 those	with	complete	
MH	vs.	aED;	13/18,	(72%)	vs.	10/36	(28%),	p=0.003	at	1	year,	8/16,	(50%)	vs.	3/24,	(8%),	p=0.008	at	









adult	 data	 confirm	 rapid	 early	 and	 sustained	MH	 in	 CD	 is	 associated	 with	 less	 frequent	 clinical	
relapses,	 fewer	 hospitalisations	 and	 reduced	 surgical	 resections	 (1,6-8,192).	 Paediatric	 studies	
prospectively	 comparing	 long	 term	outcomes	based	on	endoscopic	MH	are	 limited	but	 suggest	a	
positive	impact	of	early	MH	on	longer	term	outcomes	(178,193-195).		
Anti-TNF	agents	are	widely	used	for	induction	and	maintenance	of	remission	in	CD	and	a	range	of	












This	 study	 cohort	 is	 an	 extension	 of	 our	 previously	 described	 prospective	 study	 (Australia	 New	
Zealand	 Clinical	 Trails	 Registry-	 ACTRN12612001032842)	 of	 newly	 diagnosed	 children	 with	
predominantly	 luminal	 CD	 (<16	 years)	 treated	 with	 EEN	 and	 early	 thiopurines	 (<3	months	 from	




2014	 with	 a	 minimum	 of	 12	 months	 follow	 up	 and	 complete	 paired	 clinical,	 biochemical	 and	
endoscopic	assessment	before	and	after	EEN	were	included.	12	children	were	excluded	(9	without	
paired	 endoscopy,	 2	 with	 incomplete	 follow	 up	 endoscopy	 and	 1	 with	 isolated	 proximal	 small	
intestinal	 CD).	 Phenotype	 data	 including	 patient	 characteristics:	 endoscopy,	 radiology,	
biochemistry,	concurrent	treatments	and	outcomes	were	prospectively	collected.	Thiopurines	(TP)	
















IM’s	was	at	 the	discretion	of	 the	 treating	gastroenterologist.	Our	primary	aim	was	 to	 investigate	




Infliximab	 (IFX)	 or	 Surgery.	 Data	 on	 sustained	 CS/IFX/Surgical	 free	 remission	 was	 collected	 on	
children	completing	from	1	year	up	to	4	years	of	follow	up	and	the	impact	of	post	EEN	endoscopic	





All	 statistical	 calculations	 were	 performed	 using	 IBM	 SPSS	 version	 22	 and	 Graph	 Pad	 Prism	
Software.	Descriptive	data	is	reported	as	an	Inter-Quartile	range.	Categorical	and	continuous	data	
were	analysed	using	 fisher	exact,	Chi	 square	and	unpaired	 t	 test.	Baseline	phenotype,	 laboratory	
and	 endoscopy	 variables	 pre	 and	 post	 EEN	 induction	 were	 compared	 between	 children	 with	
sustained	remission	vs.	relapse	and	those	with	early	MH	vs.	active	endoscopic	disease	(aED).	Kaplan	
Meir	survival	analysis	was	performed	to	evaluate	time	to	relapse	(mandating	IFX	or	CS	or	Surgery)	






data	 with	 median	 follow	 up	 of	 46	 months	 (95%CI	 36-46)	 were	 analysed.	 Follow	 up	 assessment	
including	 endoscopy	 were	 undertaken	 after	 induction	 course	 of	 EEN.	 While	 aiming	 for	 repeat	




was	delayed	 for	 several	 days	 to	 accommodate	practical	 issues.	 The	median	duration	of	 EEN	was	
8.57	weeks	(IQR	7.7-9.5weeks)	and	median	time	between	pre	and	post	EEN	assessment	8.6	weeks	
(IQR	 8-10	weeks).	 Time	 to	 follow	 up	 endoscopy	 after	 the	 course	 of	 EEN	 in	 those	with	 active	 vs.	
inactive	clinical	disease	were	similar	(55	vs.	61	days,	p=0.2).	
After	completion	of	EEN,	45	(83%)	were	in	clinical	remission;	39	(72%)	in	biochemical	remission;	18	
(33%)	children	had	complete	mucosal	healing	 (SES=0);	10	 (19%)	near	complete	healing	 (SES	1-3);	
26(48%)	had	incomplete	healing	with	mild	disease	activity	in	17	(31%)	and	9	(17%)	with	moderate	
disease	 activity.	 45/54	 (83%)	 Children	 relapsed	 over	 3	 years	 and	were	managed	with	 IFX	 (n=36,	
67%),	 Intestinal	 resection	 (n=6,11%),	 Intestinal	 resection	 and	 IFX	 (n=2)	 and	 CS	 (n=1).	 Repeat	
induction	course	of	EEN	or	Tacrolimus	was	not	utilised	in	any	of	our	cohort.	7/54	(13%)	of	children	
were	intolerant	to	thiopurines	and	were	switched	to	methotrexate.	
Comparison	 of	 clinical	 characteristics	 and	 outcomes	 for	 those	 with	 complete	 mucosal	 healing	
(SES-CD	0)	vs.	active	endoscopic	disease	(SES-CD≥1).	

















post	 EEN	 endoscopy	 in	 those	 with	 SR	 and	 a	 longer	 follow	 up	 of	 the	 sustained	 remission	 group	




























Mean	Age	 12.2	 12.67	 0.92	























































































Table	 5.2.	 Comparison	 of	 Demographic	 and	 Clinical	 Characteristics	 pre	 and	 post	 EEN	 between	
children	with	sustained	remission	vs.	relapse	in	the	first	year	
		 Sustained	remission	(n=23)	 Relapse	(n=31)	 P	
Mean	Age(SD)	 11.9(2)	 12.8(1.8)	 0.08	







































































Mean	time	from	diagnosis	to	TP	use	 4.1weeks(2.2)	 5.16	weeks(3.1)	 0.09	






	 Odds	ratio		 Significance	 95%	 CI	 for	 Odds	
ratio	










12	 children	 were	 excluded	 due	 to	 lack	 of	 or	 incomplete	 post	 induction	 endoscopy.	 Sustained	
remission	at	1,	2	and	3	years	after	EEN	induction	and	early	IM’s	for	those	excluded	from	the	study	













ulcers.	 	 Near	 complete	MH	 did	 not	 give	 significantly	 improved	 SR	 over	 more	 active	 endoscopic	
disease.	
Relapse	 was	 progressively	 more	 frequent	 in	 those	 with	 aED	 vs.	 complete	 MH;	 Relapse	 was	







has	 support	 from	 recent	 studies.	 A	 placebo	 controlled	 RCT	 with	 adalimumab	 in	 adults	 with	
moderate-severe	CD	demonstrated	the	positive	impact	of	early	(12	week)	complete	MH	(SES-CD=0)	
on	Week-52	outcomes.		In	this	study,	a	“1-point	increase	in	Week-12	SES-CD	score	was	associated	






to	 superior	 outcomes,	 this	 concurs	with	 our	 findings	 as	 only	 those	with	 complete	MH	had	 good	
outcomes	(245-246)	
	
Our	 early	 mucosal	 healing	 rates	 following	 EEN	 therapy	 are	 comparable	 (33%)	 to	 our	 previous	
reports	of	44%.	(175)	Our	study	 is	also	the	first	to	prospectively	examine	the	 impact	of	early	EEN	
induced	 mucosal	 healing	 on	 important	 real-life	 long	 term	 clinical	 outcomes	 i.e	 need	 for	




Our	 study	was	not	designed	 to	address	 the	 impact	of	early	 IM’s	use	on	early	mucosal	healing	or	
subsequent	 clinical	 outcomes.	 Most	 children	 commenced	 IM’s	 around	 4	 weeks	 as	 has	 been	










of	 CRP	 (94%	 vs.	 65%,	 p=0.04,	 however	 CRP	 value	 at	 diagnosis	 was	 higher	 in	 those	 with	 active	








In	our	 current	 study,	we	did	not	examine	 serological	 immune	 response,	 genetic	 and	microbiome	
signatures	 to	 predict	 disease	 course	 and	 /or	 therapeutic	 response	 as	 suggested	 by	 recent	 data.	
Using	 systems	 dynamic	 analysis	 approach,	 Dubinsky	 et	 al	 confirmed	 small	 bowel	 involvement,	
perianal	 disease	 and	 increased	 serological	 immune	 response	 to	 be	 strongly	 associated	 with	
complicating	 paediatric	 CD	 (196).	 Recently,	 Haberman	 et	 al	 also	 documented	 that	 microbial	
signatures	from	Ileal	tissue	provided	a	modest	predictive	value	with	higher	AP0A1	gene	expression	
and	 Veillonella	 to	 Blautia	 ratio	 associated	 with	 a	 better	 sustained	 steroid	 free	 remission	 (197).	
These	 observations	 suggest	 further	 comprehensive	 studies	 are	 warranted	 combining	 detailed	
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clinical,	 endoscopic,	 serological,	 genetic	 and	 microbiological	 signatures	 to	 predict	 disease	
outcomes.	 In	 conclusion,	 we	 demonstrate	 that	 early	 complete	 MH	 post	 EEN	 induction	 predicts	
sustained	 remission	over	 and	beyond	3	 years	 on	maintenance	 Immunomodulators	 and	 that	 only	
complete	MH	(SES-CD=0)	provides	improved	outcomes.		Our	data	also	indicates	that	early	mucosal	














































3 years FU = 16  
Sustained remission = 8/16 (50%) 
New relapse = 0 
 
3 years FU = 19  
Sustained remission = 1/19 (6%) 
New relapse = 0 
 
N = 54  
1 year FU 
Sustained remission= 13/18 (72%) 
Relapse during the 1st year=5/18 
• Infliximab (IFX) = 4 
• Intestinal Resection (IR) =1 
aED = 36/54 
2 years FU = 16  
Sustained remission = 8/16 (50%) 
New relapses = 3, (IFX =3)  
 
1 year FU 
Sustained remission = 10/36(28%) 
Relapse during 1st year = 26/36 
• IFX=22 
• IR=2, IR/IFX = 2 
• CS=1 
2 years FU = 24 
Sustained Remission=3/24 (12.5%) 
New relapses =7, (IFX=5, IR+IFX=5) 
 
(2 < 2 year FU) (12 < 2 year FU) 
(5 < 2 year FU) 























































Introduction:	 Mucosal	 healing	 (MH)	 is	 a	 vital	 endpoint	 in	 CD	 and	 can	 be	 achieved	 by	 exclusive	
enteral	 nutrition	 (EEN).	 Faecal	 microbiome	 studies	 report	 EEN	 coincides	 with	 reduced	 bacterial	
diversity,	 however	 the	mucosa-associated	microbiome	 (MAM)	 is	 distinct	 and	 poorly	 reflected	 in	
faeces.	Aims	&	Methods:	We	 characterize	 the	MAM	of	 pinch	biopsies	 collected	 at	 diagnosis	 and	
after	completion	of	EEN	(Median	7.9	weeks,	95%	CI=7.5-8.2	weeks)	from	8	treatment	naïve	children	
diagnosed	with	CD;	and	relate	changes	 in	profiles	with	correspondent	endoscopic	disease	activity	
scores	 (SES-CD).	 16S	 rRNA	 gene	 amplicon	 libraries	 of	 MAM	 communities	 were	 produced	 and	
sequenced	using	Illumina	MiSeq	platforms	and	analysed	using	QIIME	and	related	packages.	Results:	
Clinical	 and	 endoscopic	 scores	 for	 all	 children	 improved	 after	 EEN	 with	 complete	 (4/8)	 or	 near	













Crohn’s	 disease	 (CD)	 incidence	 and	 prevalence	 are	 rising,	with	 approximately	 25%	 of	 new	 onset	
patients	 diagnosed	 during	 childhood	 and	 with	 a	 more	 severe	 disease	 burden	 (2-4).	 For	 these	
patients,	exclusive	enteral	nutrition	(EEN)	is	now	widely	accepted	as	an	effective	induction	therapy,	
with	 a	 clinical	 remission	 rate	 equivalent	 to	 steroids	 but	 more	 importantly,	 superior	 mucosal	
remission	 rates	 of	 40-70%	 (11-12,	 175).	 Despite	 the	 success	 of	 EEN,	 little	 is	 known	 about	 the	
mechanisms	 of	 these	 interventions	 promoting	 mucosal	 healing,	 or	 why	 some	 patients	 are	 non-
responders.	 In	 that	 context,	 our	 understanding	 how	 the	 gut	 microbiota	 is	 affected	 by	 EEN	 is	
relatively	 deficient.	 Recent	 studies	 exploring	 the	 stool	 microbiota	 during	 EEN	 in	 paediatric	 CD	
demonstrate	 reductions	 in	microbial	 diversity	 along	with	 improvement	 in	 clinical	 disease	 activity	
scores.	 These	 alterations	 include	 the	 depletion	 of	 specific	 bacteria	 such	 as	 Faecalibacterium	
prausnitzii,	which	is	widely	considered	to	be	beneficial	for	its	anti-inflammatory	properties	(14-16),	





in	 the	 child	with	 CD	 showed	 reduced	microbial	 diversity,	 increased	 levels	 of	 Proteobacteria	 and	
lower	 levels	 of	 Bacteroidetes	 species	 compared	 to	 the	 healthy	 control.	 These	 changes	 corrected	
post-EEN	with	reduction	 in	Proteobacteria	and	 increase	 in	Bacteroidetes	and	Firmicutes	phyla,	 to	
become	more	 similar	 to	 healthy	 controls.	 These	 authors	 concluded	 that	 EEN	 restores	 the	MAM	
diversity,	but	this	is	in	contrast	with	two	recent,	larger	studies	noted	above.		
In	summation,	while	EEN	promotes	MH	in	most	patients,	there	are	conflicting	results	arising	from	
the	 limited	 studies	 of	 the	 changes	 in	 stool	 microbiota	 and	 MAM	 during	 EEN,	 and	 a	 lack	 of	
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microbiome	 studies	 paired	 with	 endoscopic	 data.	 Here,	 we	 present	 the	 results	 of	 a	 prospective	
cross-sectional	 study	 to	 characterise	 the	 MAM	 of	 treatment-naïve	 children	 diagnosed	 with	 CD	
before	and	after	 EEN;	 and	 relate	 changes	 in	 these	MAM	profiles	with	 correspondent	endoscopic	
disease	activity	scores	(SES-CD).		
Methods:	
This	 study	 cohort	 is	 an	 extension	 of	 our	 previously	 described	 prospective	 study	 (Australia	 New	
Zealand	Clinical	Trials	Registry—ACTRN12612001032842)	of	newly	diagnosed	children	with	CD	(<16	
year)	 offered	 EEN	 or	 steroids	 as	 induction	 therapy	 and	 commenced	 on	 early	 thiopurines.	 Those	
electing	 to	use	EEN	 induction	 therapy,	were	offered	either	Nutrison	 (1	Kcal/ml,	Nutricia	UK,	40	g	






offered	 to	 participate	 in	 this	 pilot	 study.	 Institutional	 Ethics	 approval	 was	 granted	 and	 written	
consent	obtained	from	patients	and	parents.	Mucosal	biopsies	were	collected	from	ileum,	Caecum	




Clinical	 and	 biochemistry	 data	 including	 PCDAI	 and	 CRP	 were	 collected	 prospectively	 and	








Microbial	DNA	was	 extracted	 from	all	 the	samples	using	 the	 repeated	bead	beating	method	and	
column	 purification	 (199).	 Briefly,	 each	 pinch	 tissue	 biopsy	 was	 transferred	 into	 2-ml	 screw	 cap	
tubes	containing	0.4	g	of	zirconia/silica	beads	(0.1	mm	and	1.0	mm,	Daintree	Scientific,	St.Helens,	
Tasmania,	Australia)	 and	600	µL	of	 Lysis	Buffer	 (500	mM	NaCl,	 50	mM	Tris-HCl	 (pH	8.0),	 50	mM	
EDTA	and	4%	(w/v)	sodium	dodecyl	sulfate).	The	sample	was	homogenized	at	5000	rpm	for	60	s	for	
three	15	s	 intervals	using	 the	Precellys®24	 (Bertin	 Instruments,	Montigny-le-Bretonneux,	France).	
Total	 genomic	DNA	was	 extracted	 from	 the	 lysate	 and	purified	 using	 a	Maxwell®	 16	 Tissue	DNA	









5’-	 GTC	 TCG	 TGG	 GCT	 CGG	 AGA	 TGT	 GTA	 TAA	 GAG	 ACA	 GAC	 GGG	 CGG	 TGW	 GTR	 C	 -3’.	 The	
amplified	 products	were	 cleaned	using	Agencourt	 AMPure	 XP	 beads	 (Beckman	Coulter,	Danvers,	




bp)	 was	 excised	 and	 purified	 using	 the	Wizard®	 SV	 Gel	 and	 PCR	 Clean-Up	 System	 (Promega,	
Madison,	 WI)	 and	 subsequently	 with	 Agencourt	 AMPure	 XP	 beads	 (Beckman	 Coulter,	 Danvers,	
MA)	according	 to	 manufacturer’s	 instructions.	 Samples	 were	 quantified	 using	 the	QuantiFluor®	
dsDNA	 Sample	 Kit	 on	 the	Quantus™	 Fluorometer	 (Promega,	 Madison,	 WI).	 All	 samples	 were	
normalized	to	4	nM	final	concentration	and	then	pooled	into	a	single	microcentrifuge	tube.	Paired-
end	 sequencing	 was	 performed	 using	 the	 Illumina	 MiSeq	 platform	 (Illumina,	 San	 Diego,	 CA),	





abundance	 (<0.001%),	with	 a	Phed	 score	of	 lower	 than	20,	or	 samples	producing	 less	 than	1000	
sequences	 meeting	 these	 criteria	 were	 removed	 and	 not	 analysed	 further.	 The	 remaining	
sequences	were	 clustered	 into	 operational	 taxonomic	 units	 (OTUs)	 by	 PyNAST	 (201)	with	 a	 97%	
sequence	 identity	 threshold	 against	 the	 Green	 genes	 core	 set	 database	 version	 13.8	 (202).	 The	
generated	 biom	 table	 was	 normalised	 by	 CSS-normalization.	 Alpha	 (within-sample)	 and	 beta	
(between-sample)	 diversity	 metrics	 were	 calculated	 using	 QIIME.	 Chao1	 (203)	 was	 used	 as	 an	
estimator	 for	 richness	 of	 the	 community.	 Distance	 between	 samples	 was	 represented	 by	 the	











La	 Jolla,	 CA).	 Paired	 t-tests	 were	 performed	 to	 compare	 Chao1	 and	 specific	 genus-level	 groups	




8	 children	 (5	 females)	 completed	 exclusive	 course	 of	 EEN	 (Median	 7.9	 weeks,	 95%	 CI=7.5-8.2	
weeks)	 and	had	a	 complete	 clinical,	 endoscopic	 and	 sequential	MAM	dataset,	which	 included	68	








further	 confirming	 improvements	 in	 patient	 symptoms	 and	 gut	 inflammation.	 Based	 on	 these	
results,	we	conclude	that	all	8	patients	not	only	responded	positively	to	EEN	induction	therapy,	but	
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result	 in	 a	 reduction	 of	 alpha	 (within	 sample)	 MAM	 diversity	 in	 these	 children,	 and	 this	 was	
confirmed	 by	 analysis	 of	 the	 Chao1	 scores	 for	 individual	 samples,	 which	 showed	 a	 reduction	
following	EEN	(p=0.02)	(Table	6.2).	Interestingly,	our	sub-analysis	of	the	change	in	Chao1	diversity	
scores	 for	 patients	 showing	 complete	 endoscopic	 MH	 (SES-CD=0)	 compared	 to	 incomplete	 MH	


































a	healthy	control	 subject,	are	 shown	 in	Figure	2.	There	appeared	 to	be	no	strong	 influence	 from	
anatomical	 site	 on	 these	 profiles,	 at	 the	 Phylum	 level	 of	 classification,	 with	 the	 Firmicutes	 and	
Bacteroidetes	 phyla	 being	 the	 most	 dominant	 in	 all	 these	 samples.	 However,	 the	 relative	
abundance	 of	 the	 Bacteroidetes	 was	 increased	 in	 most	 samples	 from	 the	 CD	 patients	 and	





The	MAM	communities	 of	 pCD	patients	 can	be	differentiated	by	 their	 initial	 SES-CD	 score	 and	
respond	similarly	to	the	combined	effects	of	EEN	and	mucosal	healing			




visits.	 Interestingly,	 the	MAM	profiles	 for	 the	patient	with	the	two	 lowest	 initial	SES-CD	scores	 (4	
and	11)	were	distinctly	different	from	the	other	6	patients	(SES-CD	scores	of	15-30),	resulting	in	the	
MAM	profiles	from	this	pilot	study	being	separated	into	distinct	“groups”.	The	MAM	profiles	for	all	

































Pt 02, 05, 04,18,11,22 
Diagnosis =SES-CD~ (15-30) 
Pt 01 Diagnosis SES-CD score 4  






































The	 changes	 in	 the	 MAM	 in	 response	 to	 EEN	 therapy,	 and	 their	 relationships	 with	 endoscopic	
disease	 activity	 are	 crucial	 for	 understanding	 EEN	 mechanism	 of	 action.	 In	 this	 novel	 study	 of	
modest	sample	size	we	explored	changes	in	MAM	following	EEN	in	children	with	CD.	Employing	16S	
rRNA	 gene	 sequencing,	 we	 confirmed	 an	 overall	 reduction	 in	 MAM	 diversity	 following	 EEN.	
Previous	 studies	 indicated	 reduction	 in	 stool	 microbial	 diversity	 post	 EEN	 to	 be	 a	 crucial	 step	
associated	with	 clinical	 remission	 but	 our	 study	 is	 the	 first	 to	 document	 significant	 reduction	 in	
mucosal	microbial	diversity	to	be	associated	with	complete	mucosal	healing	(p=0.003).			
	A	significant	increase	in	the	relative	abundance	of	Lachnospiraceae	family,	particularly	Dorea	genus	
and	 reduction	 in	 the	 relative	 abundance	 of	 Faecalibacterium	 community	 were	 observed.	 These	
findings	 are	 given	 additional	 relevance	 by	 a	 recent	 paediatric	 study	 exploring	 longitudinal	 stool	




Whether	 increased	 abundance	 of	Dorea	 in	 patients	 following	 EEN	 is	 a	 reflection	 of	 its	 sustained	
growth	during	period	of	nutritional	starvation	or	a	consequence	of	reducing	inflammation	requires	
further	 studies.	 In	 a	 recent	 study	 exploring	MAM	 in	 20	 adults	 undergoing	 Ileocolonic	 resection,	
Mondot	et	al.	observed	a	fourfold	increase	of	Lachnospiraceae	taxa	following	Ileocolonic	resection	
(ICR),	more	specifically	increased	proportion	of	Dorea	longicatena	and	Bacteroides	plebeius	in	those	
maintaining	 endoscopic	 remission	 post-ICR	 (207).	 It	 is	 also	 possible	 that	 key	 microbiome	 shifts	
following	EEN	are	caused	by	alteration	in	the	nutritional	ecology	of	the	large	bowel,	which	favours	




persistence	 and	 recovery	 in	 the	 gut	 is	 associated	 with	 improved	 health	 outcomes	 in	 adult	 CD	
patients	 via	 prolonged	 remission.	 (198,199)	 In	 contrast,	 several	 studies	 have	 challenged	 the	
presumptive	protective	role	of	Faecalibacterium	prausnitzi,	with	greater	abundance	 in	those	with	
active	 CD	 at	 diagnosis	 compared	 to	 healthy	 controls	 (2087-209)	 and	 a	 significant	 reduction	 of	
Faecalibacterium	spp.	post	EEN	in	those	with	greater	remission	(14).		
As	such,	reduction	in	mucosal	abundance	of	Faecalibacterium	spp.	following	EEN	in	our	study	are	in	
agreement	with	previous	 studies.	 (14)	 	Our	data	again	 suggests	 that	Faecalibacterium	 spp.	while	
considered	beneficial,	may	not	be	required	for	mucosal	healing	as	part	of	the	mechanisms	driven	






Whether	 reduction	 in	 bacterial	 diversity	 following	 EEN	 is	 a	 cause	 or	 consequence	 of	 mucosal	
healing	 needs	 further	 elucidation.	 It	 is	 plausible	 that	 a	 significant	 reduction	 in	 bacterial	 diversity	



































































Epidemiological	 trends	 suggest	 IBD	 is	 an	emerging	global	disease	with	 rising	prevalence	 in	newly	
industrialised	 nations.	 A	 recent	 systematic	 review	 suggests	 the	 incidence	 of	 IBD	 in	 newly	
industrialised	 nations	 such	 as	 Asia,	 Africa	 and	 South	 America	 is	 increasing	 while	 the	 prevalence	
remains	static	in	Europe	and	North	America	(211).	Rates	of	IBD	in	immigrant	populations	have	also	
increased	 dramatically,	 as	 reported	 by	 a	 recent	 Canadian	 health	 administration	 study	 (212).	





recent	 case	 control	 study	 of	 incident	 cases	 of	 IBD	 and	 matched	 controls	 from	 the	 Asia	 Pacific	
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region.	 Ng	 et	 al.	 reported	 a	marked	 protective	 effect	 of	 breast	 feeding	 for	 12	months	 (adjusted	
Odds	 ratio	 0.10)	 and	 a	 greater	 risk	 of	 developing	 IBD	with	westernised	diet	 (increased	 juice	 and	
cereal	 intake)	 (214).	 A	 Canadian	 population	 based	 birth	 cohort	 study	 also	 reported	 a	 strong	
protective	effect	of	rural	residency	during	early	childhood	years,	with	a	lower	incident	rate	ratio	of	
0.58	(0-10	years)	and	0.72	(10-17	years)	(215).	A	strong	association	was	also	seen	between	early	life	
exposures	 and	 a	 complicated	 clinical	 course	 of	 Crohn’s	 disease	 in	 a	 recent	 large	 paediatric	
longitudinal	cohort	study.	Breast	feeding	was	protective	and	maternal	smoking	was	associated	with	
risk	 of	 complicated	 clinical	 course	 (216).	 These	 epidemiological	 trends	 strongly	 support	 the	
contribution	of	 lifestyle	 related	 factors	 to	 the	risk	of	developing	and	the	clinical	course	of	 IBD,	 in	
particular	of	Crohn’s	disease	(which	is	what	your	thesis	is	on).		
	
Dietary	 factors	 are	 closely	 linked	 with	 intestinal	 epithelial	 and	 immune	 biology	 and	 may	
contribute	to	pathophysiology	of	IBD	
	
Although	 diet	 is	 the	 most	 frequently	 reported	 life	 style	 risk	 factor	 associated	 with	 IBD	 flare	 by	
patients,	 there	 are	 limited	 prospective	 studies	 examining	 the	 role	 of	 diet	 in	 contributing	 to	 or	
perpetuating	inflammation	in	IBD	(26).	Prospective	lifestyle	and	dietary	risk	cohort	studies	suggests	
a	preventative	role	of	 fibre	 intake	from	fruits,	vegetables	and	an	adverse	association	with	animal	
proteins	 and	 trans-unsaturated	 fats	 (24-25).	 More	 recently,	 studies	 have	 linked	 specific	 dietary	
factors	 with	 intestinal	 inflammation.	 Animal	 and	 in-vitro	 human	 intestinal	 ecosystem	 studies	
provide	first	hand	evidence	of	epithelial	barrier	dysfunction,	aberrant	mucosal	 immune	responses	
and	 unhealthy	 microbiota	 from	 secondary	 to	 emulsifiers	 and	 saturated	 fats	 exposures	 (28,29).	





IBD.	 The	 authors	 link	 evidence	 of	 dietary	 factors	 such	 as	 high	 sugar,	 high	 fat,	 low	 fibre	 diet	 on	
mucus	layer,	intestinal	barrier	function,	bacterial	clearance	and	regulatory-T	cells	in	animal	models	
and	cell	lines	(217).	
Linking	 dietary	 factors	 with	 causation	 and	 perpetuation	 of	 IBD	 is	 highly	 intricate,	 as	 it	 involves	





studies	 as	 they	 can	 retain	 genetic	 and	 biologic	 characteristics	 of	 human	 intestine.	 There	 are	
limitations	 of	 HIO;	 they	 are	 monolayer	 of	 epithelial	 and	 mesenchymal	 cells	 and	 lack	 the	 vital	
context	of	immune	cells	and	the	neuronal	enteric	system	(218).	Incorporating	immune	and	enteric	




A	 disabling	 CD	 can	 be	 defined	 as	 one	 that	 is	 associated	 with	 frequent	 relapse,	 development	 of	
penetrating	and/or	structuring	or	perianal	disease	and	need	for	surgery.	Data	from	EPIMAD	registry	
suggest	that	clinical	predictors	at	diagnosis	are	insufficient	in	predicting	disabling	CD	in	children	but	





A	 prospective	 multicentre	 paediatric	 study	 recently	 examined	 clinical,	 serological,	 genetic	 and	
microbiome	 factors	 associated	 with	 complicated	 CD,	 defined	 as	 change	 from	 inflammatory	
phenotype	 to	 structuring	 and	 fistulising	 CD.	 At	 a	 median	 follow	 up	 of	 3	 years,	 78/913(8.5%)	




In	 another	 recent	 large	 study	 of	 1442	 children	 with	 CD,	 clinical	 factors	 associated	 with	 risk	 of	
intestinal	resection	were	examined.	Authors	reported	a	25%	actuarial	risk	of	intestinal	resection	at	
10	 years	 and	 complicating	 phenotype	 at	 diagnosis	 as	 the	 only	 clinical	 predictor	 for	 surgical	
resection	(222).	
Results	 from	 population	 based	 cohort	 studies	 remind	 us	 that	 treatment	 algorithms	 based	 on	
symptom	 severity	 alone	 are	 insufficient	 and	 a	 greater	 emphasis	 should	 be	 given	 to	 addressing	
factors	strongly	associated	with	disabling	disease	course.		
	
Chapter	 2,	 investigated	 the	 value	 of	 choosing	 EEN	 vs.	 CS	 induction	 therapy	 at	 diagnosis	 in	 the	
setting	 of	 routine	 early,	 dose	 optimised	 TP	 use	 on	 clinical	 outcomes	 over	 the	 first	 2	 years.	 	We	
confirmed	benefits	of	 EEN	with	 superiority	over	CS	 in	 reducing	 linear	 growth	 failure	 (7%	vs.26%,	
p=0.002),	steroid	dependency	(7%	vs.	43%,	p=0.002)	and	improving	sustained	response	to	IFX	(86%	
vs.	 67%,	 p=0.02).	 Choosing	 EEN	 over	 CS	 did	 not	 alter	 early	 surgical	 outcomes	 with	 comparable	
intestinal	 resection	 rates	 (6.6%	 vs.	 7.6%)	 in	 those	 with	 inflammatory	 phenotypes	 at	 diagnosis.	




There	 are	 several	 limitations	 to	 our	 study,	 including	 its	 retrospective	 design,	 bias	 of	 changing	
treatment	 paradigms	 with	 time	 (increase	 in	 use	 of	 anti-TNF’s)	 and	 lack	 of	 propensity	 score	
matching,	 a	 more	 accurate	 measure	 of	 intervention	 in	 observational	 cohort	 studies.	 However,	
benefits	of	choosing	EEN	over	CS	as	a	first	 induction	agent	were	apparent	 in	our	study,	despite	a	
higher	baseline	clinical	and	endoscopic	disease	scores	in	those	treated	with	EEN.		
There	 is	growing	evidence	confirming	superiority	of	EEN	over	CS	as	an	 induction	 therapy	beyond	




towards	a	 lower	anti-TNF’s	use	at	2	years	 (24%	vs.	40%).	Despite	a	higher	proportion	with	 linear	





prospective	GROWTH	 cohort	 study,	 outcomes	 over	 2	 years	were	 compared	 between	 EEN	 vs.	 CS	
induction	therapy.	Higher	short	term	clinical	remission	rates	in	those	with	mild-moderate	CD	and	a	
trend	towards	better	linear	growth	recovery	was	seen	in	those	treated	with	EEN	over	CS	(224).	
Disease	 relapse,	 complication	 rates	 (GROWTH	CD)	were	similar	 to	previous	 reports,	 regardless	of	
first	use	of	EEN	or	CS	(224).	











These	 studies	 provide	 first	 hand	 evidence	 that	 effect	 of	 EEN	 on	 CD	 activity	 may	 be	 related	 to	
exclusion	 of	 normal	 table	 foods.	 This	 has	 led	 to	 searches	 for	more	 palatable	 normal	 food	 based	
therapeutic	 diets	 in	 CD	 which	 can	 both	 induce	 and	 maintain	 remission.	 There	 are	 many	 recent	
publications	 focussing	 on	 this	 area.	 A	 summary	 of	 recent	 dietary	 intervention	 studies	 report	
improvement	 in	 CD	 related	 symptoms,	 and	 in	 some	 cases	 biomarkers,	 but	 they	 lack	 endoscopic	
defined	outcomes	(Table	3)228-235	
The	 Crohn’s	 disease	 Exclusion	 diet	 (CDED)	 is	 one	 such	 dietary	 approach	 that	 involves	 excluding	
dietary	 factors	 previously	 associated	 with	 disruption	 of	 mucus	 layer	 (gluten,	 dairy,	 animal	 fat,	




refractory	 cohort	 of	 patients	with	 loss	 of	 response	 to	 Infliximab	 despite	 dose	 escalation	 (17/21,	
70%)	 and	 combination	 therapy	 (18/21,	 80%)	 with	 immune-modulators	 and	 previous	 intestinal	
resection	 (7/21,	 30%).	 Clinical	 remission	 was	 reported	 in	 13/21	 (65%)	 and	 CRP	 normalisation	 in	
















antigens	 has	 been	 assessed.	 Twenty-nine	 adults	 completed	 IgG4	 targeted	 exclusion	 diet	 with	












Specific	carbohydrate	diet	 is	 another	 elimination	 diet	 excluding	 simple	 carbohydrates,	 starch,	











































































































completed	12	weeks	EEN	 therapy	with	65%	clinical	 remission	and	54%	radiologic	 remission	 rates	
(238).	
In	another	adult	 study	 including	41	adults	with	entero-cutaneous	 fistula/internal	penetrating	and	
structuring	 CD,	 75%	 of	 patients	 experienced	 fistula	 closure	 and	 60%	 of	 those	 with	 stricturing	
phenotype	observed	clinical	remission	(239).	
A	 recent	 English	 study	 also	 reported	 the	 role	 of	 EEN	 to	 optimise	 surgical	 outcomes	 for	 adult	


















associated	 with	 improved	 outcomes	 at	 1	 year.	 Good	 vs.	 poor	 early	 endoscopic	 response	 was	
associated	with	reduction	in	endoscopic	confirmed	relapse	(53%	vs.	100	%,	p	=	0.02),	anti-TNF	use	
(33%	vs.	88	%,	p	=	0.01)	and	hospitalisation	(40	vs.	88	%)	at	1	year.	This	study	is	first	to	evaluate	the	











Despite	 limitations	 of	 design	 and	 size,	 our	 data	 suggest	 that	 early	 MH	 is	 more	 important	 than	
baseline	endoscopic	disease	severity	as	better	1	year	outcomes	were	seen	in	those	with	early	good	





A	 subset	 of	 patients	 underwent	MR	enterography	 at	 diagnosis	 and	 after	 EEN	 (16/26,60%),	 of	 14	
with	active	 ileal	Crohn’s	disease	at	diagnosis,	3/14	 (21%)	achieved	transmural	healing(TMH).	 	We	
did	not	sub-analyse	our	EEN	induced	TMH	due	to	small	numbers.	However,	only	a	small	proportion	
of	 children	 achieved	 combined	 transmural	 (TMH)	 and	mucosal	 healing	 2/14(15%),	 similar	 to	 low	
rates	reported	by	the	Image	kids	study	(21/151,	14%)	(242).	
The	 Image	 kids	 study	 also	 reported	 high	 rates	 of	 TM	 healing,	 despite	 active	mucosal	 disease	 in	
83/151(55%).	 This	 observation	 is	 in	 contrast	 to	 our	 observation,	 as	 we	 observed	 a	much	 higher	
proportion	 of	 children	 with	 TM	 disease	 activity	 8/14(57%)	 on	 MRE,	 despite	 good	 endoscopic	
response	(SES-CD=0-3).	
This	could	be	explained	by	the	follow	up	MRE	after	EEN	being	performed	too	early,	within	a	median	




Finally,	 the	 objective	 of	 the	 Image-Kids	 study	was	 not	 to	 assess	MRE	 response	 to	 a	 therapeutic	
intervention	and	so	disease	duration,	time	to	repeat	MRE	was	heterogeneous	(242).			







Chapter	 4,	 demonstrated	 the	 individual	 reliability	 of	 symptom	 based	 scores	 (Paediatric	 Crohn’s	
disease	 activity,	 PCDAI),	 biochemistry	 (CRP)	 and	 stool	 biomarker	 (Faecal	 Calprotectin,	 FC)	 in	
predicting	 endoscopic	 disease	 activity	 (SES-CD)	 in	 new	 diagnosis	 Crohn’s	 after	 induction	 therapy	
with	 EEN	or	 steroids.	We	explored	 the	 contention	 that	 control	 of	 symptoms	does	not	 equate	 to	
effective	control	of	mucosal	 inflammation.	We	demonstrated	that	CRP	and	FC	were	more	reliable	
than	symptom	scores	but	not	sufficiently	accurate	for	predicting	mucosal	disease	recovery	to	serve	
as	 sole	 primary	 endpoints	 for	 treatment	 of	 Crohn’s	 disease.	 We	 confirmed	 that	 the	 patient	
reported	 symptom	 score	 (PCDAI)	 is	 the	 least	 reliable,	 blood	 test	 (CRP)	 had	moderate	 utility	 and	
stool	biomarkers	(FC)	had	the	best	individual	utility	in	predicting	degree	of	mucosal	inflammation.		









The	 value	 of	 surrogate	 biomarkers	 in	 predicting	 mucosal	 and	 transmural	 healing	 was	 further	
examined	 in	 a	 recent	 large	 prospective	 paediatric	 study.	 Poor	 concordance	 of	 mucosal	 and	
transmural	 disease	 was	 again	 demonstrated	 with	 11-43%	 of	 those	 with	 active	 mucosa	 and/or	
transmural	disease	reported	to	be	 in	clinical	 remission.	A	FC	cut-off	 level	of	300mg/gm	predicted	










availability	 of	 transmural	 healing	 data	 due	 to	 lack	 of	 paired	 MRE.	 It	 is	 therefore	 unclear	 if	
transmural	and	histological	inflammation	was	persistent	in	children	with	elevated	FC	>	200	μg/gm,	
despite	 complete	 endoscopic	 mucosal	 recovery.	 Despite	 these	 limitations,	 our	 results	 suggest	 a	
composite	 score	 using	 combination	 of	 clinical	 and	 objective	 markers	 can	 predict	 endoscopic	
healing.		
		
Chapter	 5,	 reported	 longitudinal	 outcomes	 of	 54	 newly	 diagnosed	 children	 with	 predominantly	
luminal	CD	(<16	years)	completing	EEN	induction	and	early	thiopurine	(<3	months	from	diagnosis).	
Early	 Complete	 MH	 was	 observed	 in	 18/54	 (33%),	 near	 complete	 in	 10/54(19%).	 	 Control	 of	
symptoms	 or	 improvement	 of	 serum	 biomarkers	 with	 clinical	 remission	 alone	 was	 inferior	 in	
predicting	 endoscopic	 remission.	 The	 complete	 early	 disappearance	 of	 ulcers	 (mucosal	 healing)	
after	EEN	was	associated	with	greater	sustained	remission	(SR).		
Relapse	 was	 progressively	 more	 frequent	 in	 those	 with	 active	 endoscopic	 disease	 (aED)	 vs.	
complete	MH;	26/36	(72%)	vs.	5/18(28%),	p=0.003	at	1	year,	21/24(92%)	vs.	8/16,	(50%),	p=0.008	

























































CD	 (CALM	 study),	 comparing	 a	 tight	 control	 arm	 using	 biomarkers	 vs.	 a	 conventional	 clinical	
management	 arm.	 Complete	 endoscopic	 remission	 rates	 were	 18%	 (CDEIS=0)	 compared	 to	 46%	









at	 the	 end	 of	 EEN	 induction	 therapy,	 all	 these	 relapsed	 over	 the	 following	 year	 leading	 to	 later	




It’s	 time	to	embrace	a	 treat	 to	 target	approach	but	 it	 remains	unclear	 if	 therapeutic	adjustments	
based	 on	 biomarkers	 are	 superior	 to	 repeated	 endoscopy	 examination	 in	 achieving	 mucosal	
healing.	On	one	hand,	 FC	and	CRP	are	excellent	non-invasive	biomarkers	but	up	 to	20%	patients	
with	a	normal	CRP<5mg/L	and	FC<250	μg/	gm	of	stools	at	48	weeks	failed	to	achieve	MH	(CDEIS<4)	
in	 the	 CALM	 study	 (248).	 The	 other	 important	 issue	 is	 that	 escalation	 of	 therapies	 based	 on	
biomarker	alone	may	result	in	overtreatment	of	substantial	proportion	of	patients.		
Repeat	endoscopic	evaluation	 to	make	 treatment	adjustments	aiming	 for	MH	 is	 less	well	 studied	
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but	 emerging	 data	 suggest	 that	 this	 approach	 may	 be	 feasible	 and	 is	 associated	 with	 superior	
outcomes	 if	 escalation	 of	 therapy	 is	 performed	 in	 those	 failing	 to	 achieve	 MH	 (249).	 Recently	
published	 expert	 paediatric	 guidelines	 suggest	 that	 repeat	 endoscopic	 examination	 for	 MH	 is	
helpful	 but	 it	 does	 carry	 a	 risk	 associated	 with	 multiple	 general	 anaesthetics	 and	 health	 care	
burden.	Future	trials	need	to	evaluate	whether	treating	to	an	endoscopic	endpoint	is	better	than	a	
biomarker	based	approach	(250).	
Chapter	 6	 reports	 longitudinal	mucosal	 associated	microbiome	 changes	 (MAM)	 at	 diagnosis	 and	
after	completion	of	EEN	(Median	7.9	weeks,	95%	CI=7.5-8.2	weeks)	from	8	treatment	naïve	children	
diagnosed	with	 CD.	 Employing	 16S	 rRNA	 gene	 sequencing,	we	 confirmed	 an	 overall	 reduction	 in	
MAM	diversity	following	EEN.	Previous	studies	indicated	reduction	in	stool	microbial	diversity	post	





therapy.	 These	 findings	 are	 interesting	 as	 a	 recent	 paediatric	 study	 exploring	 longitudinal	 stool	
microbiome	 changes	 in	 CD	 demonstrated	 lower	 levels	 of	 Lachnospiraceae	 to	 be	 associated	with	
absence	 of	 mucosal	 healing	 (non-responders)	 to	 Immunomodulators	 and	 biologics.	 Whether	













and	 thiamine	 biosynthetic	 pathways.	 In	 contrast	 an	 increase	 in	 stool	 pH,	 stool	 sulphides	 and	
spermidine/putrescine	 biosynthesis	 are	 documented	 (14,15).	 Dunn	 et	 al	 recently	 reported	 an	
increase	 in	 the	 functional	metagenomics	pathways	 involved	 in	 the	degradation	of	 environmental	
pollutants	 and	 xenobiotics	 and	 reduction	 in	 NOD-like	 receptor	 signalling	 in	 those	 with	 a	 poor	
clinical	response	to	EEN	(134)	
There	 are	 only	 limited	 data	 on	metabolomic	 changes	 during	 dietary	 interventions.	 	 In	 treatment	
naïve	children	with	CD,	stool	metabolic	alterations	similar	 to	 those	seen	 in	children	on	EEN	were	
observed	 on	 a	 CD-TREAT	 diet,	 an	 ordinary	 diet	 with	 a	 nutritional	 composition	 identical	 to	 EEN	
(Svolos	V	et	al.	ECCO,	March	2016).		As	we	look	to	using	more	normal,	less	restrictive	diets	than	EEN	
in	CD,	these	observations	are	encouraging	but	preliminary.	However,	a	more	objective	endpoint	of	
response	 such	as	mucosal	or	endoscopic	healing	are	 required	 to	establish	 therapeutic	efficacy	of	









Exclusive	 Enteral	 Nutrition	 (EEN)	 in	 children	 with	 Crohn’s	 disease	 (CD)	 is	 associated	 with	 early	
complete	mucosal	 healing	 (MH)	 in	up	 to	one-third	of	 children.	Completeness	of	mucosal	 healing	
following	EEN	induction	is	strongly	associated	with	improved	long-term	outcomes.	In	the	two	thirds	
of	 children	 failing	 to	 achieve	 complete	 MH	 the	 majority	 will	 suffer	 moderate	 to	 severe	 clinical	




Our	 data	 reinforces	 the	 finding	 of	 poor	 correlation	 of	 endoscopic	 measured	 inflammation	 with	
symptom	based	scores	 (PCDAI);	serum	CRP	and	stool	calprotectin	are	more	reliable.	A	composite	
score	of	normalised	PCDAI,	CRP	and	stool	calprotectin	cut-off	<500	µgram	was	the	most	reliable	for	
predicting	 endoscopic	 remission	 during	 EEN	 induction	 therapy.	 	 a	 practical	 prediction	 tool	 for	





of	 knowledge	 of	 microbiome	 signatures	 associated	 with	 endoscopic	 mucosal	 healing	 were	
examined	 in	a	 limited	cohort	of	 children	with	CD.	Our	 results	 indicate	 that	 reduction	 in	bacterial	





persistence	 and	 recovery	 in	 the	 gut	 is	 associated	 with	 improved	 health	 outcomes	 in	 adult	 CD	
patients	via	prolonged	remission.	Our	results	are	in	agreement	with	two	previous	stool	microbiome	
studies	 reporting	 reduction	 in	 F.	 prausnitzii	subgroups	 studies	 on	 EEN	 (Jia	 et	 al.	 FEMS	
Microbiol.2010,	 Gerasimidis	 et	 al.	 Inflamm	 Bowel.	 Dis	 2014)	 suggesting	 Faecalibacterium	 spp.	
presence,	while	 beneficial,	may	 not	 be	 required	 for	mucosal	 healing	 as	 part	 of	 the	mechanisms	
driven	by	EEN	induction	therapy.		
We	observed	significant	increases	in	the	relative	abundance	of	Lachnospiraceae	family,	particularly	
Dorea	 genus.	While	 enhanced	 growth	 of	Dorea	 during	 periods	 of	 nutritional	 starvation	 could	 be	
related	 to	 its	 inherent	 ability	 to	 thrive	on	host	derived	nutrients	 (mucins	 and	proteoglycans)	but	
these	 findings	 may	 be	 relevant,	 as	 two	 recent	 paediatric	 studies	 exploring	 longitudinal	 stool	
microbiome	changes	in	CD	also	identify	of	Lachnospiraceae	Spp.	as	key	bacterium	associated	with	




in	 those	 achieving	 MH	 vs.	 active	 endoscopic	 disease.	 Lack	 of	 resources	 precluded	 our	 planned	




and	 metabolic	 pathways	 of	 endoscopic	 responders	 vs.	 non-responders	 will	 enhance	 our	
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we	 are	 performing	 the	 study	 and	what	 is	 involved	 should	 you	wish	 to	 participate.	 	 The	 study	 has	 been	 approved	 by	 the	 Royal	 Children's	
Hospital,	Ethics	Committee.		There	is	no	obligation	to	take	part	in	this	study,	if	you	do	not	wish	to.	
Crohn's	disease	(CD)	is	a	chronic	inflammation	of	the	bowel	that	can	significantly	interfere	with	quality	of	life	and	growth.		When	diagnosed	






























any	disease.	 	 If	 you	 take	part	 in	 the	 study,	 that	 number	will	 increase	by	 an	 extra	 12	biopsies	 to	 gain	 research	 information.	 	 It	will	 add	 an	
additional	5-10minutes	to	the	length	of	the	procedure	but	will	not	cause	any	additional	problems	for	you.		It	will	not	damage	the	gut	and	the	
risk	of	bleeding	from	biopsies	is	minimal.		The	stool	specimen	will	be	analysed	for	the	range	of	organisms	in	it.		
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We	would	like	to	invite	you	/	your	child	to	participate	in	a	study	to	help	us	care	for	children	with	Crohn’s	disease.		This	information	sheet	is	to	











on	 steroids	 reporting	 clinical	 remission	having	active	mucosal	disease.	 	 Exclusive	Enteral	Nutrition	 (EEN)	 for	 a	minimum	of	8	weeks	 is	now	










your/your	 child’s	 care	 is	 keen	 to	 offer	 you	 this	 treatment	 but	 will	 consider	 alternative	 treatment	 strategies,	 if	 he/she	 thinks	 they	 are	 in	
your/your	 child’s	 best	 interests	 and	 this	 takes	 precedence	 over	 any	 study	 requirements.	 	 The	 other	 treatment	 traditionally	 offered	 in	 this	
setting	is	steroid	medication.		Steroids	are	easier	to	administer	but	have	more	side	effects	and	are	less	effective	in	treating	the	inflammation.	
If	you	consent	to	take	part	in	the	study,	while	under	anaesthetic	for	the	first,	diagnostic	Endoscopy	and	Colonoscopy	we	will	collect	additional	







the	microflora	that	 is	adherent	to	the	bowel	 lining;	to	 look	at	the	T	regulatory	cells	 in	the	bowel	 lining	and	to	 look	at	the	expression	of	cell	
messenger	proteins	(cytokines)	in	the	bowel	lining.			Normally	we	take	20-30	biopsies	(each	2mm	diameter)	from	children	to	best	assess	the	
cause,	severity	and	distribution	of	any	disease.		If	you/your	child	take	part	in	the	study,	that	number	will	increase	by	an	extra	12	biopsies	to	




After	 completing	 8	 weeks	 treatment,	 either	 EEN	 or	 an	 alternative	 such	 as	 steroids	 if	 this	 was	 chosen,	 we	will	 repeat	 the	 Endoscopy	 and	
Colonoscopy	to	establish	if	satisfactory	healing	has	taken	place.		We	think	this	is	the	best	way	to	determine	the	next	step	in	management.		You	
are	not	obliged	to	have	the	follow	up	procedures	if	you	do	not	wish	to.		If	you	do,	and	if	you	still	wish	to	be	part	of	the	study,	we	will	again	
collect	 additional	 biopsies,	 an	 extra	 12,	 and	 additional	 blood	 10mls,	 to	 look	 at	 the	 T	 regulatory	 cells.	 	 Your	 subsequent	 treatment	will	 be	

















































 Baseline PCDAI, CRP, Iron studies, Calprotectin, Endoscopy, MRE 
Screen for Biological/Immunomodulators –QTB, HBV, HCV, EBV, CMV, Varicella 
*Optimise vaccination, including siblings 
TPMT status  
Early biologics for fistulising CD – Medicare link 
http://www.medicareaustralia.gov.au/provider/pbs/drugs1/files/4237-initial-fistulising-crohn-
disease.pdf 
EEN /Steroids induction therapy 
*Wait 3 weeks after live vaccines (MMR, Varicella) before starting IM/Biologics 
* No Live vaccines with Steroids 




1st OPD Visit after confirmed diagnosis (2-3 weeks) 
PCDAI, CRP, Iron Studies  
If not already on start 6MP/Imuran (3 weeks after live vaccine) grading up to 2-2.5mg/kg/day  
*Calprotectin –to see early response 






2nd OPD /Endoscopy visit (End of EEN, usually on 6MP or Imuran) 
  
Follow up – Calprotectin, PCDAI, CRP, Endoscopy, MR Enterography (Usually 8-10 weeks) 
                                                                            
No mucosal remission    Partial Mucosal remission  Mucosal 
remission 
(< 3 months of 6MP/Imuran)   Continue IM     Continue IM 
Continue IM    PBS funded Inflximab/Second Course EEN- Clinical relapse
  
* If severe inflammatory luminal disease, consider Compassionate Infliximab 
**If associated fistulising Peri-anal disease, consider PBS Biologics 
*** If stricturing Ileal disease consider early limited resection and prescribe Post-operative antibiotics for 3 
mo 
****Follow up endoscopy 3 mo post resection to evaluate for endoscopic relapse in terminal ileum 
      
 
 Clinical Follow up – Calprotectin, PCDAI, CRP, BMI Z scores 
   
              Secondary end points:  at 1, 2 years and last follow up 
Hospitalisation    
Disease relapse   
Steroid therapy 
Resection 
Need for Biologics 
Progression of Clinical Phenotype 



















































The	 Relative	 Abundances	 of	 Dorea	 and	 Faecalibacterium	 spp.	 in	
the	Mucosa	Associated	Microbiome	of	Newly	Diagnosed	Children	
with	 Crohn's	 Disease	 Are	 Differentially	 Affected	 by	 Exclusive	




Accelerated	 Step	 up	 use	 of	 Infliximab	 is	 associated	 with	 greater	
sustained	 primary	 response	 rates	 in	 Paediatric	 luminal	 Crohn’s	





Early	 induction	 with	 Infliximab	 in	 Paediatric	 Crohn’s	 disease	 is	















A	 prospective	 study	 of	 new	 cases	 of	 Paediatric	 Crohn’s	 disease	
treated	with	Exclusive	Enteral	Nutrition:	Early	clinical,	biochemical,	
mucosal	and	transmural	outcomes		
Digestive	Diseases	Week		
San	Diego,	May	2012	
Exclusive	Enteral	Nutrition	and	Mucosal	healing.	
	
Paediatric	 IBD	 symposium,	
Melbourne,	April	2011	
	
	
